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ENGLISH SUMMARY 
One of the most prevalent diseases in the world is chronic obstructive pulmonary 
disease (COPD). 64 million people are estimated to have COPD leading to 3 
million annual deaths. As many as 430,000 Danish citizens could have COPD.  The 
cost of managing COPD is therefore considerable; in Denmark for example, 10 
percent of the total annual healthcare budget for citizens older than 40 years can be 
related to COPD. In 2012, telehealthcare was highlighted as a technology with the 
potential to increase primarily the health-related quality of life for COPD patients, 
while also relieving some of the fiscal pressure in the healthcare sector. But this 
potential had not been demonstrated in large-scale randomized evaluations with 
high quality health economic evaluation. A pragmatic clinical trial with trial-based 
economic evaluation, the Danish TeleCare North trial, was therefore designed in 
order to assess the effectiveness and cost-effectiveness of a particular telehealthcare 
solution implemented in North Denmark Region and the design of the trial and its 
results are presented in this thesis. At the same time, the TeleCare North trial was 
embedded in a “national action plan for the dissemination of telemedicine” meant to 
test telehealthcare technology, implementation models and potential benefits of 
telehealthcare across different initiatives and settings. This action plan was used as 
a foundation for deciding whether or not to disseminate telehealthcare to different 
patient groups in 2015. 
Contrary to expectations, the TeleCare North trial demonstrated no difference in 
health-related quality of life and the telehealthcare solution was not cost-effective 
for all included COPD patients. But there was a potential to target the solution to 
patients with severe COPD, because they were likely to be most cost-effective. The 
results also indicate that implementation could have a strong impact on cost-
effectiveness, more so than health- or socio-demographic factors. The results from 
the TeleCare North trial were used directly in a decision to implement the 
telehealthcare solution to patients with severe COPD in Denmark and lead to 
considerable debate nationally. This debate is an actual account of the usefulness of 
health economic evaluation for decision making that could also be used to adapt the 
health economic evaluation approach. It is argued that one lesson from the national 
decision process is that there is no getting around making decisions that are based 
on underlying evaluations with a balanced outcome focus and randomization. 
Another lesson is that telehealthcare interventions are difficult to implement and 
that effects of implementation can be hard to foresee, quantify and make visible, 
which challenges the current approach to health economic evaluation. 
Furthermore, it is argued that trial-based economic evaluation of telehealthcare in 
Denmark has gained momentum, which creates the pressing issue of designing even 
better trial-based economic evaluations that simultaneously address challenges with 
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isolating cause-and-effect relationships, learning curves and with generalizing 
results. Based on recent developments in realist evaluation, experiences with 
conducting the economic evaluation of TeleCare North and participating in the 
national decision debate, four principles for health economic evaluation of complex 
telehealthcare interventions is outlined in order to facilitate more informed health 
economic designs of telehealthcare in the future that should ultimately answer if 
telehealthcare is cost-effective, for whom, why and under what circumstances.
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DANSK RESUME 
En af de mest udbredte sygdomme i verden er kronisk obstruktiv lungesygdom 
(KOL). Alene i Danmark skønnes 430.000 danskere at have KOL, hvilket leder til 
3.300 årlige dødsfald. Omkostninger til behandling og pleje af KOL-patienter er 
derfor også betydelige: I Danmark skønnes 10 procent af det samlede årlige 
sundhedsbudget for borgere ældre end 40 år at være relateret til KOL. I tiden 
omkring 2012 blev telemedicin fremhævet som en teknologi, der havde potentiale 
til at øge livskvaliteten for KOL-patienter, samtidig med, at det kunne reducere 
KOL-relaterede omkostninger. Men potentialet var ikke blevet påvist i store 
lodtrækningsforsøg med indlejret sundhedsøkonomisk evaluering. Et stort 
lodtrækningsforsøg med sundhedsøkonomisk evaluering blev derfor designet i regi 
af det danske TeleCare Nord initiativ. Formålet var at vurdere effektiviteten og 
omkostningseffektiviteten af den valgte telemedicinske løsning og dets resultater er 
præsenteret i denne afhandling. TeleCare Nord initiativet var på samme tid en del af 
en national handlingsplan for udbredelse af telemedicin, som skulle sikre, at der 
blev testet telemedicinsk teknologi, implementeringsmodeller og effekter af 
telemedicin på tværs af forskellige regioner. Handlingsplanen blev brugt som et 
beslutningsgrundlag i 2015 for, hvorvidt bestemte telemedicinske løsninger kunne 
bruges af forskellige patientgrupper. 
Mod forventning viste TeleCare Nord ingen forskel i livskvalitet for de inkluderede 
KOL-patienter og den telemedicinske løsning var heller ikke generelt 
omkostningseffektiv for alle omfattede KOL-patienter. Men der var et potentiale i 
at målrette løsningen til patienter med svær KOL, fordi sandsynligheden for at dette 
ville være omkostningseffektivt var særlig stor. Resultaterne viser også, at 
implementering kan have en stærk indvirkning på omkostningseffektiviteten, måske 
endda mere end kliniske eller socio-demografiske faktorer. I 2015, blev resultaterne 
fra TeleCare Nord brugt direkte i en beslutning om at implementere den 
telemedicinske løsning til patienter med svær KOL i Danmark. Men beslutningen 
førte også til en betydelig national debat. Denne debat illustrerer et konkret 
eksempel på brugbarheden af sundhedsøkonomisk evaluering, der kan anvendes til 
at genoverveje måden, hvorpå sundhedsøkonomisk evaluering foretages. I 
afhandlingen argumenteres der for eksempel for, at man ikke kommer udenom at 
træffe beslutninger, der er baseret på underliggende evalueringer, der har et 
afbalanceret resultat-fokus og lodtrækning. Der argumenteres også for, at 
telemedicinske interventioner er vanskelige at implementere og at virkningerne af 
implementering kan være svære at forudse, kvantificere og synliggøre, hvilket 
udfordrer den nuværende tilgang til sundhedsøkonomisk evaluering. 
Endvidere hævdes det, at sundhedsøkonomisk evaluering indlejret i kliniske forsøg 
af telemedicin i Danmark har fået en vis anerkendelse, men at dette også 
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nødvendiggør at der designes endnu bedre sundhedsøkonomiske evalueringer. 
Udover at skulle løse udfordringer med at isolere årsag-virkning sammenhænge, 
skal sundhedsøkonomisk evaluering også kunne håndtere læringskurver og 
generalisering af resultater. Baseret på den seneste udvikling i virkningsevaluering, 
erfaringer med at gennemføre den sundhedsøkonomiske evaluering af TeleCare 
Nord og som part i den nationale debat om telemedicin, opstilles der fire principper 
for sundhedsøkonomisk evaluering af komplekse telemedicinske interventioner som 
er skitseret med henblik på at starte en ny agenda for sundhedsøkonomisk forskning 
i telemedicin, der i sidste ende skal kunne svare på, om telemedicin er 
omkostningseffektiv, for hvem, hvorfor og under hvilke forudsætninger.
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CHAPTER 1. INTRODUCTION 
The “Global Burden of Disease Study” has recently published prevalence and 
incidences estimates of acute and chronic diseases for 188 countries from 1990 to 
2013 (1). One conclusion is that the global prevalence of chronic disease, e.g. 
cancer, cardiovascular disease, chronic pulmonary disease, diabetes, mental 
disorders and musculoskeletal disease, is high (1). And as a result of the ageing of 
the World’s population and better treatment of previously life-threatening diseases, 
the incidence of chronic diseases has risen (1). Estimates made by the World Health 
Organization (WHO) make chronic diseases responsible for roughly half of the 
global burden of disease (46%) (2), numbers that have been echoed by Centers for 
Disease Control and Prevention that has estimated that roughly half of all American 
adults have one or more chronic health conditions (3). Based on a prevalence study 
made in the Capital Region of Denmark (4), the Danish Health Authority have a 
slightly lower estimate of around one-third of all Danish citizens (5).  
One of the most prevalent chronic diseases is chronic obstructive pulmonary 
disease (COPD) (1,6,7). The WHO projects that 64 million people have COPD 
worldwide which account for more than 3 million annual deaths (8). COPD has 
been shown to be a major health problem in the European Union with between 4-
10% of citizens diagnosed with COPD within member states (9). In Denmark, the 
Danish Lung Association estimates that as many as 430,000 Danish citizens could 
suffer from COPD (10) with a scientific study setting the prevalence to 9% (11). 
According to the latest analysis on the disease burden in Denmark, around 3,300 
Danish citizens die due to COPD each year (6% of total number of deaths) (12). 
Additionally 2,500 die each year of other causes related to COPD (13). This makes 
COPD the fourth largest cause of death in Denmark (13). 
Because of the high prevalence, the costs of treating and caring for COPD patients 
are considerable. There is no systematic data collection on the global costs of 
treating and caring for COPD patients, but a survey conducted in 2003 in seven 
countries (Canada, France, Italy, the Netherlands, Spain, the UK and the US) 
demonstrates “significant” healthcare sector costs (14). In Denmark, previous 
studies have concluded that as much as 10 percent of the total annual healthcare 
budget for citizens older than 40 years is related to COPD and the recent disease 
burden study estimated costs in the vicinity of £250 million per year, primarily due 
to hospital admissions and productivity loss (12).  
This creates a burning platform, because many countries have at the same time been 
struggling to recover from a global recession since 2008 (15). In Denmark, the 
Danish Ministry of Finance downgraded the economic outlook for both 2011 and 
2012 to an increase in Gross Domestic Product (GDP) of only 1% in December 
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2011 (from 1.3 and 1.8%, respectively) (16). According to the Organisation for 
Economic Co-operation and Development (OECD) economic survey for Denmark 
published in early 2012, public expenditure had risen in Denmark from 51% of 
GDP in 2007 to 58% in 2010 (17). This financial context combined with projections 
of the demographic development, the prevalence of disease and a potential for 
future shortages in recruiting healthcare personnel was seen as constituting a threat 
to the Danish publically funded healthcare system by challenging its fiscal 
sustainability (18). However, another OECD analysis had argued that achieving 
better health outcomes at lower costs in Denmark were possible (19). It was argued, 
that this end could be achieved by focusing more on patient pathways across state, 
regions and municipalities thereby reducing waste by duplication of tasks, having 
more control over spending and better incentives for providing cost-effective 
services across sector-boundaries (19). Given the structure and funding of the 
Danish health care system, the government had ample opportunity to encourage and 
potentially put political and financial pressure on the municipalities - and in 
particularly the regions - for containing public expenditure e.g. by focusing more on 
cross-sectorial initiatives and -technologies (20). 
Telehealthcare was highlighted as one of different solutions that could be 
implemented as an integrated part of patient pathways across sectors in order to 
meet some of the threats facing the healthcare system (20). It was argued that 
telehealthcare had the potential to address challenges with an ageing population and 
a rising number of patients with chronic disease thereby also relieving some of the 
fiscal pressure in the healthcare sector (20,21). There had previously been some 
experience with telehealthcare in Denmark, also for COPD patients (22–24), but 
mostly mono-sectorial small-scale demonstration projects, with only 40% of them 
in current operation and without having formally evaluated effects (25). 
Internationally though, telehealthcare had been systematically reviewed for COPD 
patients and this evidence suggested a potential for increased health-related quality 
of life and reduced hospital contacts (26,27). But reviews also demonstrated a 
shortage of randomized studies with cost and cost-effectiveness evaluation and that 
those that did exist were small feasibility or pilot studies, meaning that the evidence 
base for the effects and costs of telehealthcare were relatively limited (26,27). 
These results were not unique at the time. Systematic reviews had been conducted 
with similar results for other chronic diseases or as syntheses of several other 
chronic diseases (e.g. asthma, cardiovascular disease, chronic heart failure, diabetes 
and hypertension) (28–32).  
In 2012, there was therefore a scientific need for more and larger randomized 
studies with embedded cost-effectiveness analyses that could be used to assess 
whether or not telehealthcare could in fact deliver on its promises in settings closer 
to routine practice. A pragmatic clinical trial, the Danish TeleCare North trial, was 
designed in order to assess the effectiveness and cost-effectiveness of a particular 
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telehealthcare solution implemented in North Denmark Region and the results from 
this trial are presented in this thesis. 
At the same time, the TeleCare North trial had a connection to a Danish “national 
action plan for the dissemination of telemedicine” that was published in 2012 (33).  
The intention with the action plan was to ensure that new and larger telehealthcare 
initiatives were tested and evaluated in Denmark from 2013-2015 and that they 
included cost-evaluations (33). In addition to the TeleCare North trial, the action 
plan also funded a second large-scale telehealthcare initiative with formal - but 
differently designed – economic evaluation of its telehealthcare solution (33). 
Based on the generated evidence from the action plan, a decision was taken in late 
2015, to implement telehealthcare to patients with COPD. 
This decision-process is interesting to describe. In many countries there are an 
agreed form and process for conducting economic evaluation that are used in 
national health care resource allocation. In the United Kingdom (UK) for instance, 
the National Institute for Health and Care Excellence (NICE) systematically assess 
new medical technologies in order to estimate both their effectiveness and cost-
effectiveness (34). Their program is comprehensive and has since year 2000 
covered 566 Health Technology Assessments (HTAs) with cost-effectiveness 
evaluation of pharmaceuticals, medical devices, diagnostics and clinical procedures 
(34,35). Healthcare resource allocation by some form of HTA approach including a 
standard methodology for including economic analyses is also implemented in 
many other countries such as New Zealand, Australia, Korea, Thailand, Canada, 
Scotland, Ireland, Germany, the Netherlands, Norway and Sweden. But this is not 
the case in Denmark. In fact, broad and systematic evaluation has in general been 
neglected since the late 1990s and never really pursued whole-heartedly. 
Responsibility for conducting HTAs was originally placed at the Danish Health 
Authority but funds had been reduced over several years (36,37). In 2008, the 
Danish Health Authority decided to downsize most of its activities on HTAs (it 
continued to assess vaccines for the national child vaccination program and other 
pre-planned HTAs) (36,37). Some HTAs with health economic evaluation are 
instead conducted by the five Danish regions in collaboration, but no more than one 
or two are published each year and the process for choosing technologies for 
assessment is more ad hoc than systematic. 
Most Danish national politicians have historically been reluctant to use health 
economic evaluations, especially if these evaluations take the form of cost-utility 
analyses; presumably because it ultimately involves putting an explicit price on the 
lives or health of its citizens. Even though new guidelines for economic evaluation 
used for reimbursement of medicine was published in 1997 (38), a broad and 
systematic approach to decision-making that uses economic evidence that “smells” 
like standard cost-effectiveness evaluation remains a politically hot topic to this 
day. Up until now, the Danish regions have instead made decisions on the use and 
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funding based on recommendations made by two advisory expert panels 
(“Koordineringsrådet for ibrugtagning af sygehusmedicin (KRIS)” (39) and “Råd 
for anvendelse af dyr sygehusmedicin (RADS)” (40) (no English translations). But 
these panels only evaluate hospital medicine and are not allowed to include cost in 
their recommendation calculus. Although the Danish Regions in the spring of 2016 
decided to establish a new advisory organ called “Medicinrådet” (no English 
translation), that should make decisions on whether or not to buy expensive hospital 
medicine by including costs in the calculus, it is still unclear if this organ would 
later include recommendations for other technologies than hospital medicine (the 
very last paragraph in the document describing the overall principles for 
“Medicinrådet” hints that the model could be expanded to other technologies in the 
future (41)) or what type of economic evidence should be included to make these 
decisions.  
There are two main implications of this. One is that no consensus exists on whether 
or not health economic evidence should be included at all in healthcare decision-
making on technologies other than pharmaceuticals; what characteristics this health 
economic evidence should have or the best way to include and combine economic 
evidence. Another implication is that health economic research is usually decoupled 
from national prioritization. But what happens if results from a large-scale cost-
utility evaluation alongside a clinical trial were to be used in a national action plan 
combining results from other initiatives meant to inform a decision on whether or 
not to disseminate telehealthcare to different patient groups? How would economic 
evidence be applied by decision-makers?  
This actual account of the usefulness of health economic evaluation in a national 
decision-process is combined with health economic theory, experiences with 
conducting the TeleCare North evaluation and topics from realistic evaluation in 
order to suggest a new research agenda for an adapted approach to trial-based 
economic evaluations of complex telehealthcare interventions. Four normative 
principles is outlined in order to facilitate more informed health economic designs 
of telehealthcare in the future that should ultimately answer if telehealthcare is cost-
effective, for whom, why and under what circumstances. 
1.1. RESEARCH QUESTIONS 
1.1.1. RESEARCH QUESTION ONE (RQ1): THE WITHIN-TRIAL 
EFFECTIVENESS AND COST-EFFECTIVENESS OF THE TELECARE 
NORTH TRIAL 
As described above, the results and conclusions from the evaluation of the TeleCare 
North trial are important and interesting in themselves, because larger comparative 
studies with more rigorous health economic evaluation have been requested 
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scientifically for telehealthcare in several systematic reviews. The first research 
question for this thesis therefore becomes: 
“Is the chosen telehealthcare solution for COPD patients adopted in 
the TeleCare North initiative effective and cost-effective?” 
1.1.2. RESEARCH QUESTION TWO (RQ2): APPLICATION OF 
EVIDENCE IN A NATIONAL DECISION  
But the results are also interesting because Danish healthcare decision stakeholders 
would use, combine or at least relate to the various new economic evidence that 
were provided within the action plan to the decision-making process. How would 
that unfold? What would they focus on? The research question therefore becomes: 
“How was evidence applied in a national Danish decision-making 
context of whether or not to adopt telehealthcare?” 
1.2. OUTLINE OF THE THESIS 
The thesis outline is presented in Figure 1. The thesis sets out by describing 
relevant aspects of the theoretical foundation used (chapter 2) and the methodology 
applied (chapter 3). Article one (the systematic review in appendix 1) is essentially 
trying to answer how much evidence of health economic benefits of telehealthcare 
to COPD patients there existed in 2013 and how sound this evidence was. The 
existing evidence was informed a detailed design of a health economic evaluation 
nested in the cluster-randomized trial in TeleCare North. Article two therefore 
describes a design that would have a higher quality by including more 
recommended characteristics in a sound health trial-based health economic 
evaluation (see appendix 2). 
In order to answer RQ1, a series of empirical publications were planned and are 
divided in further three publications. Article three is the main effectiveness results 
from the TeleCare North trial that focuses on assessing gains in health-related 
quality of life (see appendix 3). Then the main results from the economic evaluation 
of TeleCare North are presented in article four (see appendix 4) for all of the 
included patients in accordance with the trial protocol. Finally, knowledge of 
potential sources of heterogeneity in cost-effectiveness is presented in article five 
(see appendix 5). This study seeks out potential subgroups of patients that are more 
or less likely to be cost-effective. A short summary of these articles is presented in 
chapter 4. 
To answer RQ2, a document analysis is performed that analyzes how evidence both 
from initiatives within the national action plan and from abroad was incorporated 
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into the national decision of dissemination of telehealthcare in Denmark that took 
place in 2015-2016 (chapter 5).  
Finally, a discussion is presented in Chapter 6, which seeks to make sense of and 
build additional theory for trial-based economic evaluation that are based on the 
theory presented in chapter 2, the experiences gained from the design process and 
results from the cost-effectiveness evaluation of TeleCare North as well as the 
analysis of the national decision. Based on this sense-making process, principles for 
“a realist sketch for health economic evaluation of complex telehealthcare 
interventions” is outlined. This is meant as a small theoretical contribution in order 
to facilitate more informed health economic designs of telehealthcare in the future.  
 
 
A realist sketch for health economic evaluation of complex telehealthcare solutions
(chapter 6)
Application of evidence in national decision (chapter 5)
Is it likely that particular subsets of COPD patients are more cost effective than others?
Heterogeneity in cost effectiveness Appendix 5
What is the cost effectiveness of the TeleCare North initiative?
Cost effectiveness Appendix 4
What are the effects of the TeleCare North initiative on health related quality of life?
Effectiveness Appendix 3
The effectiveness and cost effectiveness of the TeleCare North Trial (chapter 4)
How could a scientific study be designed in detail that could improve this knowledge base?
Study protocol Appendix 2
What is the current (in 2013) cost and cost effectiveness evidence of telehealthcare for COPD patients?
Systematic review Appendix 1
Methodology (chapter 3)
Theoretical foundations (chapter 2)
Introduction (chapter 1)
Figure 1: Thesis outline. Source: Own contribution. 
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1.3. CONTRIBUTION(S) OF THE THESIS 
In addition to providing new scientific evidence on the effectiveness; cost structure 
and cost-effectiveness of telehealthcare to COPD patients in RQ1, this thesis has 
further two main contributions.  
Firstly, by changing unit of analysis and applying a qualitative research 
methodology, the thesis seeks to place the TeleCare North trial in a health policy 
resource allocation context by describing and commenting on the national decision 
in late 2015 and early 2016. This is meant as an illustration of “what went on” 
nationally in the resource allocation for telehealthcare in order to provide an actual 
account, as opposed to a theoretical examination, of the usefulness of health 
economic evaluation for decision-making. The intention is also to draw out themes 
that can used to build additional theory on economic evaluation of telehealthcare 
that a presented in chapter 6.  
Secondly, by briefly attempting to switch philosophy of science standpoint from 
positivism to critical realism and investigate a particular evaluation methodology 
called “realistic evaluation” often applied in sociology, principles for an integrated 
evaluation process called a “realist sketch for health economic evaluation of 
complex telehealthcare interventions” is proposed that seek to transcend a 
methodological discussion of which existing evaluation approach is best suited for 
telehealthcare research. This is meant as a suggestion for a new research agenda for 
health economic evaluation of telehealthcare that, in addition to seeking to answer 
whether or not telehealthcare interventions work and for whom, also begins to focus 
on why and under what circumstances.  
Conducting the evaluation for this Ph.D.-thesis has been an unusual task.  
The results from particularly the economic evaluation have been used directly 
in a decision to disseminate the telehealthcare solution throughout Denmark. 
This gave rise to a national debate on the methodology of economic 
evaluations and the strengths and weaknesses of trial-based economic 
evaluation and other types of economic evaluations. I was part of this debate in 
the media and as invited speaker and panel member on conferences. It also 
entailed that I have used two periods throughout the Ph.D.-study - one in 2015 
and another in the spring of 2016 - where I provided additional analyses and 
counseling for the Danish government in order for them to calculate and revise 
a national business case for telehealthcare.  
The reporting of the health economic evaluation was coordinated with the 
effectiveness evaluation. This meant that the empirical economic publications 
waited almost a year for submission. It also meant that I became involved in 
the effectiveness evaluation of the TeleCare North trial by conducting most 
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data management and all quantitative analyses used in the scientific reporting 
of main and subgroup outcomes described in the trial protocol and by 
conducting further analyses of secondary effectiveness outcomes for North 
Denmark Region and the Danish Government of particularly mortality for the 
included patients. 
The amount of attention the economic evaluation received was overwhelming; 
in part because a summary report of the main conclusions from the economic 
evaluation were publically available, while the scientific articles remained 
unpublished. For example in the weeks after the main results from the 
economic evaluation was presented in November 2015, I received more than 
200 e-mails and phone calls from people in Denmark and abroad making 
enquiries of further details from the study or requesting comments on the 
national decision process.  
The clinical trial entailed a large amount of practical data collection and data 
management work for me, which is unusual for authors of economic 
evaluations. By ultimately including 1,225 patients, 2,200 paper-based 
questionnaires each with more than 80 variables were sent out and entered 
manually. 200 patients who did not respond to questionnaires were contacted 
by telephone and a much used phone hotline for patients, practitioners and 
institutions were established and manned. Similarly, the register data task was 
large by including not only national register data on all healthcare contact 
patterns, but also specific costs categories from all municipalities in North 
Denmark Region. Including municipalities in economic evaluations of 
healthcare initiatives has not been done often in Denmark and elsewhere and 
ultimately ended in 120 datasets from the included 10 municipalities alone.  
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CHAPTER 2. THEORY 
2.1. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 
As professionals in the field of health economics, we risk forgetting the people 
behind the COPD diagnosis and treatment alternatives. I would therefore like to 
begin this theoretical chapter by checking in with reality and give the reader a quick 
sense of life with COPD. Besides having a disease to fight, life with COPD can be 
hard (42). Feelings of helplessness can make it difficult to be a COPD patient and 
there is a constant fear of suffocating: 
“Anyone who has tried not to be able to breathe, know how scary and 
unpleasant an experience it is. As a COPD patient you may 
experience that even the smallest things can cause shortness of breath 
- to eat, talk on the phone or just to get nervous. Therefore, you tend 
to keep to yourself and isolate yourself in your home […]. So you can 
easily feel lonely and helpless, which can reinforce your anxiety. It 
can be difficult for family, colleagues and others to understand how 
you feel, or get them to take your condition seriously. They may think 
you just have to "pull yourself together" (translated from Danish) 
(43).  
It is actually possible to feel the effects of breathlessness with a small exercise (you 
should try it before you read further!): Take ten deep in- and exhalations and then 
put a straw to your mouth while holding your nose. Then go up and down a set of 
stairs while breathing only through the straw and see how long you can keep doing 
that. Imagine everyday life under these conditions… 
2.1.1. CHARACTERIZATION OF COPD 
Clinically COPD is defined as “a disease characterized by persistent airflow 
limitation that is usually progressive and associated with an enhanced chronic 
inflammatory response in the airways and the lung to noxious particles or gases” 
(44, p2). COPD cannot be cured and the clinical course is a gradually deteriorating 
lung function without patients necessarily being aware of it, which often leads to a 
late diagnosis at an advanced severity stage of the disease (45). The main symptoms 
of COPD are dyspnea, decreased exercise tolerance, wheezing, recurrent lung 
infections, “smoker’s cough” and abnormal sputum (46). COPD patients can 
experience some variations in their usual symptoms over time, e.g. during the day 
or from day to day (47). Yet, it is also normal that patients (depending on the 
severity of COPD) occasionally experience a number of events (exacerbations), 
where symptoms become more severe than normal variations, which requires 
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changes to the usual management of their disease (44,48). A number of other 
conditions are also associated with COPD, e.g. cardiovascular disease, metabolic 
syndromes such as diabetes, osteoporosis and mental illness (49,50). Smoking (or 
even second-hand smoking) is by far the main reason for developing COPD, but air 
pollution, childhood lung infections and genetics can also play a role (7,51).  
2.1.2. DIAGNOSIS AND ASSESSMENT OF COPD 
Diagnosis of COPD can be based on the history of symptoms, patient 
questionnaires, physical examination, pulmonary function tests, blood-gas analyses 
and chest radiography (46). Part of the goal with diagnosis is to determine the 
severity of the disease that is used to determine prognosis and treatment strategy 
(44). Pulmonary function test by spirometry is the most widely accepted instrument 
in diagnosing airflow limitation and in assessing COPD severity (44). A spirometer 
expresses airflow limitation by two variables: Forced Expiratory Volume in one 
second (FEV1) and Forced Vital Capacity (FVC). When FEV1/FVC < 0.70, it 
constitutes a COPD diagnosis (44). The severity of airflow limitation can be 
assessed with the FEV1% predicted (measured FEV in percentage of the expected 
value given the age, gender, height and race of the patient) (44). Table 1 presents 
this severity stratification, which was also applied in article 3 and 5 to analyze if 
there could be a systematic variation in effectiveness and cost-effectiveness across 
COPD severity. 
Table 1: Spirometric classification of COPD severity. Source: (44). 
 
 
The patients’ subjective experiences with dyspnea can be used to complement 
spirometry and allow for a more complete picture of the COPD condition and 
especially two questionnaires are widely used. The Medical Research Council  
Dyspnea Modified (mMRC) Scale is a questionnaire that are comprised of five 
statements that describe experiences with breathlessness from no experience 
(category one) to almost invalidating breathlessness (category 5) (52). The COPD 
Assessment Test (CAT) consists of 8 questions measuring health status that can 
result in a score from 0-40 (53). For both questionnaires, a higher score is 
representative of more severe experiences with COPD. Both questionnaires can be 
Severity
FEV1 value in %
compared to 
predicted FEV1 value 
Mild FEV1  80 %
Moderate 50 %  FEV1 < 80 %
Severe 30 %  FEV1 < 50 %
Very severe FEV1 < 30 %
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self-administered or filled in by an interviewer by asking patients to indicate the 
phrase that best describes their experience. 
In 2013, around the time of the initiation of TeleCare North, updated guidelines for 
assessing COPD severity was published that in addition to lung function tests also 
account for subjective experiences and the risk of exacerbations (44). A more 
representative picture of severity is now a combined risk assessment that are 
divided into four categories designated by A, B, C and D, as demonstrated in Table 
2 (reproduced from (44)). This classification was unfortunately not incorporated in 
the trial.   
Table 2: Combined COPD assessment classification of severity. Source: (44). 
 
 
2.1.3. THE DANISH HEALTH CARE DELIVERY MODEL 
In order to provide a context for the evaluation, but also to give the reader a sense 
of which perspectives can be chosen for health economic evaluation of technologies 
in Denmark, it is important to understand how the health care system is organized 
and funded and which sectors are currently involved in managing COPD. 
Denmark has a tax financed health care system for all Danish citizens. It covers 
treatment and care and subsidizes medicine and medical devices (54). The public 
sector in Denmark has the main obligation for providing health care; an obligation 
which is divided between the Danish state, five regions and 98 municipalities (55). 
In this division, the regions play the largest role by having the responsibility for 
both psychiatric and somatic hospital services and primary care  (55). The role of 
the 98 Danish municipalities in health care is largely confined to disease 
A = Low risk, low symptom burden
Low symptom burden (mMRC of 0-1 OR CAT score < 10) AND
FEV1 of 50% or greater (old GOLD 1-2) AND low exacerbation rate (0-1/year)
FEV1 < 50% (old GOLD 3-4) AND/OR high exacerbation rate (2 or more/year)
B = Low risk, higher symptom burden
C = High risk, low symptom burden
D = High risk, higher symptom burden
Higher symptom burden (mMRC of 2 or more OR CAT of 10 or more) AND
FEV1 of 50% or greater (old GOLD 1-2) AND low exacerbation rate (0-1/year)
Low symptom burden (mMRC of 0-1 OR CAT score < 10) AND
FEV1 < 50% (old GOLD 3-4) AND/OR high exacerbation rate (2 or more/year)
Higher symptom burden (mMRC of 2 or more OR CAT of 10 or more) AND
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prevention, home care and rehabilitation. The Danish state is the governing-body, 
advising and regulating the healthcare sector (55). A private sector exist with a few 
private hospitals and the entire operation of primary care is contracted out to 
independent general practitioners (55,56). But provision of healthcare is generally a 
public responsibility with relatively decentralized delivery (55).  
Since healthcare funding stems from general taxation at the state and municipality 
level, the regions play a reduced political role (54). Healthcare activities in regions 
are financed by block grants from the state and payment based on regional activity 
(remuneration based on Diagnose-Related Groups (DRG)). Municipalities are co-
funding the operation of regions by an activity-based payment. Municipalities 
receive a block grant from the state but otherwise collect taxes directly from 
citizens. However, the state sets a yearly ceiling on municipality taxes (54,55). 
Private co-payment or user fees exist (around 17% of the total healthcare budget), 
mainly for medicine, dental care, physiotherapy, chiropractors and for stay at 
nursing homes (54,56).  
2.1.4. USUAL PRACTICE FOR MANAGING COPD IN DENMARK 
Since 2002, COPD has been given priority as one of eight  diseases in the Danish 
public health policy (57). The Danish Health Authority has subsequently 
strengthened systematic efforts to prevent these diseases and to promote health 
within these diseases in the Danish health care system (58,59). According to 
guidelines, a typical management strategy for COPD patients in Denmark consist of 
a combination of monitoring, treatment and rehabilitation (60) and concrete 
management activities are as follows:  
Several training and counseling opportunities exist (60). All COPD patients that are 
current smokers are offered motivational counseling and help to stop smoking (e.g. 
by medicine) and are informed about the risks of continued smoking (60). All 
patients are encouraged to exercise and patients with at least moderate COPD can 
be referred to individually tailored programs for physical training (60). Patients 
with overweight or patients that experiences unexpected weight loss can be referred 
to nutrition counseling and –control (60). All COPD patients are offered education 
in the characteristics of the disease and the importance of adhering to suggested 
prevention and rehabilitation activities suggested for them (60). Finally, 
psychosocial aspects such as social isolation, anxiety or job status of each COPD 
patient’s is assessed in order to initiate relevant support initiatives that can increase 
quality of life and a well-functional daily life (60).  
Pharmacological treatment is a requirement for minimizing COPD symptoms and to 
prevent exacerbations and the concrete treatment varies depending on disease 
severity and the acuteness of illness (61). All patients can receive short-term 
inhaled airway-expanding medicine as needed to relieve symptoms; patients with 
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moderate, severe and very severe COPD can be treated with long-acting airway 
expanding medicine potentially combined with steroid inhalants if acute 
exacerbations are experienced (61). Antibiotics are frequently used during 
exacerbations to reduce inflammation as are pharmaceuticals used to relieve anxiety 
(61). Medicine for nicotine replacement is also used to support smoking cessation 
(61).  
Patients should be monitored “regularly” in order to assess disease progression and 
to support current training and counseling or to initiate new ones (60). This could 
take the form of regularly assessing COPD severity by spirometry or subjective 
experiences by MRC or CAT-scoring, but also by having different vital signs 
indicative of health status checked, such as weight, blood pressure, heart rate and 
oxygen saturation.  
Oxygen therapy are needed when lungs cannot ventilate the blood sufficiently on 
their own anymore (61). Some patients only require short-term oxygen therapy due 
to acute exacerbations while they are admitted to hospitals or in the weeks 
following discharge (61). Other patients might need long-term oxygen therapy 
(defined as at least 15 hours/day) which is often the case for very severe COPD 
patients (61). Eventually lungs can be so deteriorated that mechanical ventilation is 
necessary in order to prevent instant respiratory failure and death.   
A patient’s general practitioner (GP) takes the central role in diagnosing, treating 
and monitoring COPD patients (62). Citizens are not screened for COPD, but 
according to recommendations (60), smokers, ex-smokers or people employed in 
high risk jobs over 35 years who have pulmonary symptoms, should have a 
consultation with their GP (63). After a diagnosis of COPD and the assessment of 
COPD severity, regular monitoring by the GP is initiated in order to keep the 
COPD stable, e.g. by preventing exacerbations as much as possible (63). Depending 
on the certainty of diagnosis, severity of COPD or existence of comorbidities, 
COPD patients can also be treated and monitored at hospitals (64). Acute hospitals 
admissions are also normal during exacerbations and mechanical ventilation is 
usually also initiated at hospitals for COPD patients that are close to respiratory 
failure. Danish municipalities are, based on a clinical evaluation of a patient’s 
needs, involved in practical help, home nursing care and pulmonary rehabilitation 
of COPD patients (63,65). Community care (practical help and nursing care) is 
provided at regular intervals and training courses and counseling is offered in 
smoking cessation, exercise planning and diet (63). Community care personnel are 
not necessarily certified nurses and not specialized in COPD. 
This usual practice and typical management strategy for COPD implicate that many 
healthcare providers are involved in treating and caring for COPD patients and 
contacts to providers are frequent. In Denmark, COPD patients have recently been 
estimated to account for as many as 17,000 annual hospital admissions (2% of all 
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hospital admissions), 65,000 outpatient visits and up to 490,000 visits to general 
practitioners (12). This management strategy and the organization of Danish health 
care means that all three sectors have economic incentives for effective and cost-
effective management of COPD. 
2.2. TELEHEALTHCARE 
2.2.1. DOES TELEHEALTHCARE WORK AS A MANAGEMENT 
STRATEGY FOR COPD? 
Based on different syntheses of the available high quality evidence, the short 
answer to this question was “a hesitant yes” in 2011-2012. Systematic reviews of 
telehealthcare suggested that telehealthcare could lead to more effective treatment 
and possible even lower costs, e.g. in the Cochrane review from 2011, that focused 
on the effectiveness of telehealthcare compared to face-to-face care for COPD 
patients (26). The review found ten studies who met their inclusion criteria and 
concluded that telehealthcare was associated with no difference in mortality, higher 
health-related quality-of-life and a decrease in visits to emergency departments as 
well as reduced admissions to hospitals (26). This conclusion is largely a 
confirmation of a previously conducted effectiveness review (66) and in line with 
similar reviews being published around the same time (67,68). Although costs were 
secondary outcomes in the conducted reviews, they also concluded that a few 
studies also demonstrated a potential for telehealthcare to cut costs in the 
management of COPD (67,68).  
But several reviews have also warned that the evidence base for the effectiveness 
and especially the cost and cost-effectiveness of telehealthcare to COPD patients 
were weak (28,30,31,67–70). The reviews only found studies with few participants, 
short follow-up and across studies the participants had different health- and socio-
demographic characteristics and they applied different outcomes measures and 
several classes of telehealthcare solutions. Therefore, any systematic differences 
across disease type, type of telehealthcare solution or patient characteristics were 
hard to ascertain and it was therefore difficult to assess what worked for whom 
(28). Based on these reviews, more evidence of economic effects of larger 
initiatives in future telehealthcare research were requested that could allow 
investigators to come a little closer to telehealthcare solutions that worked for 
particular subgroups of patients (71,72). 
2.2.2. DEFINING TELEHEALTHCARE 
Tele-related technologies applied in healthcare is not just one solution with the 
same (proportion of) ingredients. A quick Google search for related terms used to 
describe the type of communication and networking technology employed in 
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healthcare (i.e. that uses eHealth, telehealthcare, telehealth, telecare and 
telemedicine as terms) yields over 20,500 hits and more than 8,500 scientific papers 
with this exact combination of keywords. There have been a few attempts to review 
the scientific literature for definitions of some of these terms. For example, Oh and 
colleagues reviewed definitions of “eHealth” in 2005, and found 51 unique but 
overlapping definitions. In 2007, Sood and colleagues found 104 peer-reviewed 
definitions of “telemedicine” (73). So it is safe to say, that the applied terminology 
used to define and describe different technologies enabling some form of treatment, 
support, monitoring and care for patients at a distance are partly overlapping, have 
complex attributes and that no commonly accepted definition exist (73–77).  
Instead, attempts to describe frameworks for various definitions of tele-related 
technologies have been developed in order to compare and contrast different 
attributes of the applied terminologies. Two of these frameworks are developed by 
Doughty and colleagues in 2007 (75). The first framework distinguishes between 
assistive technologies and telehealthcare. Assistive technologies consist of fixed 
mechanical devices (e.g. walking aids, ramps, grab rails, lifts) and electronic 
systems (orientation aids, reminder systems, environmental controls) installed at the 
patients’ homes. The focus of assistive technologies is to help citizens conduct daily 
activities at home without much involvement from institutions (i.e. healthcare or 
social care providers). Telehealthcare is used as a general term for any telecare, e-
care and telemedicine technology that support patient independence but have a 
stronger emphasis on geographical distance and involvement of institutions 
involved in protecting and promoting health. Telehealthcare therefore covers 
technologies that trigger alarms associated with health status that health 
professionals can respond to, technologies that offers lifestyle and behavior advice, 
enables proactive contact to healthcare personnel and that transmits various 
measurements indicative of a person’s wellbeing. They could also be technologies 
enabling health professionals to diagnose or even treat patients remotely from a 
medical center or hospital. The second framework view assistive technologies only 
as house adaptations and telemedicine only as hospital services with telecare pretty 
much as everything else in between (75). 
Goodwin (74) defines the differences between terms in another way: Telehealth is 
concerned with the electronic transfer of physiological data between a patient at 
home and health professionals to assist in diagnosis and monitoring of a disease. 
Telecare is about automatic and remotely monitoring patients to manage risks 
associated with independent living in their own home. Telemedicine is more 
concerned with online treatment. Regardless of framework chosen, it should be 
obvious from above that terms that describe tele-technologies employed in the 
health- and social care sector have slightly different uses and are partly overlapping.  
As in a 2012 review of telehealthcare for COPD (78), I prefer the term 
“telehealthcare” as an umbrella term to cover the definitions of telehealth, telecare 
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and telemedicine described above. This means that “telehealthcare” is not defined 
in this thesis per se, but are argued to have three important features: First, it is a 
technology that contains data from a patient – e.g. written responses or statements, 
measured physiological data, audio or video. Secondly, there is an electronic 
transfer of this data over a physical distance and thirdly, a healthcare professional 
exercise their judgment in providing personalized feedback to the patient (79).   
Defining telehealthcare by distinguishing between terms can risk implying that 
particular health professions are delivering healthcare (telemedicine is often 
associated with curative medicine, i.e. doctors, and telecare with nursing). Since the 
focus in this thesis is on attaining evidence of cost-effectiveness of the tele-
technology and not on professional boundaries, the distinction of terms seems less 
relevant. 
2.2.3. TYPICAL ELEMENTS IN TELEHEALTHCARE SOLUTIONS 
Many “modern” telehealthcare solutions combines some of the same ingredients 
(80,81). The main ingredients are a device and a number of peripheral equipment 
that can communicate with the device. The device and peripheral equipment 
enables patients to transmit data indicative of their health status to health 
professionals who are situated at some other location. Health professionals are then 
able to provide feedback (e.g. treatment and care advice and/or emotional support) 
to the patient based on the transmitted data and the patients can receive the 
feedback at a place where it is convenient for them. These core elements of 
telehealthcare are often supplemented by a deliberate delegation of monitoring 
responsibility from one health profession to another (typically from physicians or 
general practitioners to nurses). Usually, the solution also involves technology- and 
disease-specific education or training to both health professionals and patients.  
But telehealthcare solutions differ in how these ingredients are mixed. Hardware 
installations are either fixed (telephone or pc) or mobile (laptop, smartphone or 
tablet) and allow for different data to be transmitted (e.g. verbal communication, 
questionnaires, weight measurements, blood oxygen levels, blood pressure, pulse, 
expiratory flow measures etc.) that give a more or less complete picture of the 
disease that are monitored and allow for different levels of standardized responses 
to these data (from automated response of judgment to the exercising of judgment 
in each case). The technological solutions can facilitate data and/or feedback to be 
delivered either synchronously (in real time) or asynchronously (i.e. store and 
forward data and response). Patients can also track their own historical data and 
feedback to a varying degree and the monitoring data are more or less integrated 
within existing IT-systems applied by health professionals. Finally, the type, 
amount and intensity of training received by both patients and monitoring staff can 
vary as can the health professions responsible for monitoring patients.  
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So, the ingredients of telehealthcare solutions may be the same, but a telehealthcare 
intervention can be configured in a multitude of ways meaning that several aspects 
or ingredients may have different effects on the patients receiving it. And these 
effects may also differ depending on the characteristics of the target population. 
This means that the effectiveness and costs is likely to vary depending on the 
characteristics of the technology-configuration and/or the targeted patient 
population. 
2.3. HEALTH ECONOMIC EVIDENCE 
The intention with this section is not to describe and review the health economic 
literature in its technical details, but rather to give an overview of what science in 
health economics in general mean by “economic evidence” and the role it has in 
health care decision-making. 
Drummond and colleagues have published the most cited and used book on health 
economic evaluation (82). In it, they define health economic evaluation as “a
comparative analysis of two or more courses of action in terms of both their costs 
and consequences” (82, p4). A course of action is a technology in its broadest 
sense, e.g. a set of activities included in health promotion, diagnosis, treatment or 
rehabilitation of disease (83). The intended audience for economic evaluations is 
decision-makers responsible for assigning funding to particular health technologies 
(84). The role of health economic evaluation in decision-making may be described 
in the following way: 
“Whatever the context or specific decision, a common question is 
posed: are we satisfied that the additional health care resources […] 
should be spent in this way rather than in some other ways? The 
other ways these resources could be used might include providing 
health care for other patients with different conditions, reducing the 
tax burden of collectively funded health care, or reducing the costs of 
social or private insurance premiums”(82, p3).  
From the quote, two important features can be elicited. First, health economic 
evaluation is concerned with choices by focusing on the costs and health outcomes 
of different courses of action, i.e. the inputs and outputs that these technologies 
would apply and result in, thereby seeking to make criteria for decision-making 
explicit (82). Second, the theoretical assumption behind health economic evaluation 
is that of opportunity costs: Given a fixed budget, every time money is spent on one 
course of action, it displaces another course of action that could have been funded 
instead (82). So, decision-makers are “in principle” better off funding those courses 
of action that give the highest health-effect for their money (technical efficiency). 
However, health economic evidence is not the sole source of information used in 
health care resource allocation, because there can be other concerns than technical 
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efficiency. In countries that systematically assess new technologies, health 
economic evaluation is one element in health technology assessments (HTAs). An 
HTA is a systematic and multidisciplinary evaluation of health effects, economic 
effects, organizational impacts and relevant social or ethical issues (83). This means 
that a health technology can end up being prioritized/not prioritized for other 
reasons than technical efficiency (e.g. equity issues).  
There are different approaches to conducting health economic evaluation which 
includes decision modeling; trial-based economic evaluation and observational 
studies. Decision modeling are usually the preferred approach for economic 
evaluation used in health care resource allocation, e.g. as part of HTAs, since 
economic modeling provides a more comprehensive framework for decisions under 
uncertainty (82). Trial-based economic evaluation and observational studies is not 
recommended as a single data source for economic evaluation used to make health 
care decisions, but results from trial-based economic evaluations are central as input 
to health economic decision models by “feeding” these with values on resource use, 
unit costs and health effects (85). In this process, observational studies can also be 
used (85).  
Decision modeling for economic evaluation 
Economic evaluation conducted as decision models incorporates secondary data 
retrospectively from multiple published sources (85). The strengths of decision 
models are that they provide a structure to the decision problem by reflecting the 
costs and outcomes in clinical pathways or health states that patients might undergo 
and how different clinical processes or interventions may influence these pathways 
or health states (82,85). Decision models can also incorporate all relevant evidence 
into the economic analyses and compare all relevant options for courses of action 
(82,85). Decision models translates this evidence into estimates of total expected 
costs and outcomes of alternative courses of action thereby identifying which 
alternative is the best -with the available evidence- via a pre-specified decision rule 
such as a willingness-to-pay threshold for additional quality-adjusted life years 
(QALY) (82,85).  
Decision models also allow for reflection of how uncertainty in the underlying 
evidence translates into uncertainty in health care decision-making (82,85). 
Through this assessment of uncertainty, it can point to the value of more 
information from future research, i.e. instead of being forced to accept or reject a 
course of action now, the decision can be postponed until further evidence has been 
generated on model input parameters or the clinical course of the disease (86).  
Technically, a decision model uses statistical probabilities to relate a range of 
plausible consequences that are likely results of alternative courses of action under 
study (85,87). Each consequence has a cost and an outcome. Based on input to the 
model, the likelihood of each consequence is presented with transition-probabilities 
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(85,87). For each given course of action, it is possible to calculate the expected total 
costs and outcome by “rolling back” the model or by “sending” a cohort of 
hypothetical patients through the pathways (calculating the total weighted expected 
costs and outcomes) (85).  
Gathering evidence for decision modeling can be a challenging task. Single studies 
rarely compare all relevant options and there is therefore a need to build a decision 
model from many sources (82). Furthermore, a proportion of these sources may be 
generated outside the decision-jurisdiction (e.g. another country with a different 
health care system) (88). This makes some form of evidence synthesis and/or 
translation of results necessary first in order to arrive at input values for a decision 
model (82,88). In addition, the outcome measures and time horizon applied in 
clinical studies of treatment options will limit their usage for economic evaluation, 
since evidence on economic end-outcomes are usually missing (i.e. end-outcomes 
such as resource use, costs, health-related quality of life) and the follow-up period 
may be too short to capture all relevant costs and outcomes relevant for decision-
making (85). Ways to link immediate outcomes with final outcomes and 
extrapolation of costs and outcomes may therefore be necessary (85). These 
assumptions and steps taken in order to apply a model to a specific decision may 
seem speculative, but to use a famous quote from the statistician George Box on the 
use of empirical models: "Essentially, all models are wrong, but some are useful" 
(89).  
Trial-based economic evaluation  
In health research, experimental evaluation or randomized evaluation are 
considered the “gold standard” for evaluating the effects of health technologies 
(90). The most used variant, the randomized controlled trial (RCT), randomly 
assigns individual patients to one or more treatment alternatives and a control group 
in which patients does not receive treatment (90). Patients are thereafter followed in 
parallel using the same methods in order to compare outcomes between them over a 
certain time period (90). The randomization should maximize the likelihood that 
patients in the alternatives are comparable in every way except the treatment under 
consideration, which leaves only the different treatments as explanations for 
observed differences in outcomes (90). To achieve credibility in the cause-and-
effect conclusions drawn (a high internal validity), this design requires that the 
investigators follow a number of commonly accepted procedures in order to avoid 
biasing or confounding the results (91). 
Trial-based economic evaluation or “economic evaluation alongside clinical trials” 
is designed to collect primary data prospectively from individual patients within 
these randomized trials (92). The focus is on estimating incremental costs and 
incremental health outcomes of health technologies and the uncertainty surrounding 
these estimates within this single study (82,92). The treatment options compared 
and time horizon for the economic analysis is determined by the design of the 
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randomized trial (93). Data on relevant parameters used in economic evaluation 
(e.g. resource use, mortality, health-related quality of life) are collected more or less 
simultaneously with the clinical parameters from all individual patients or a subset 
of patients within the trial (93) and an incremental analysis of the costs per outcome 
measure is conducted (e.g. additional costs per QALYs gained) (93).  
The advantages of trial-based economic evaluation is the opportunity to exploit the 
trial’s high internal validity (82). The marginal costs of collecting additional data in 
the trial is also relatively low and it can be time-saving compared to collecting 
economic evidence retrospectively (82). The downsides of using trial-based 
economic evaluation for decision-making - in addition to the challenges mentioned 
in the section on decision-modeling (inappropriate comparisons, outcomes and time 
horizon) - is generally problems with generalizability (external validity) (82).  
Trial-based economic evaluation mainly embedded in trials designed for clinical 
purposes (called “piggy-backing studies”) (94) are often explanatory evaluations 
concerned with estimating the efficacy of courses of action, i.e. estimate the 
outcomes and costs of technologies under ideal circumstances (82,92). These 
studies often have a very high internal validity, but the implications could be that 
effects are overestimated. Patients could be selected based on a set of strict criteria 
leading to a sample of patients that may not have the same prognostic 
characteristics as “normal patients” would have in routine practice (e.g. patients 
selected in the trial may only be those with fewer comorbidities, that are the most 
motivated for treatment etc.). Furthermore, the activities undertaken in efficacy 
trials may not be representative of the activities that are feasible in routine practice, 
because activities in trials are more frequent or invasive, standardized, detailed or 
health professionals used in the trial may be better trained. All of these problems 
can make it unlikely to replicate the costs and health outcomes in routine practice 
thereby reducing the potential for generalization (82).  
A clinical trial can also be more specifically designed to reflect routine practice and 
serve as a better carrier of economic evaluation (82,95). These studies seek to 
estimate effects of courses of action in a setting closer to routine practice and are 
often called “effectiveness trials” or “pragmatic trials”. The idea is to balance the 
objectives of a high internal validity with larger opportunities for generalizing the 
results (93). This is done by maintaining the randomization to different courses of 
action while imposing fewer restrictions on the included patients and how they were 
followed in the duration of the trial. This would often lower the internal validity of 
the conclusions drawn, but increase the generalizability of the results. Pragmatic 
designs are actually the current recommended approach when conducting trial-
based economic evaluation (93). 
Efficacy trials and pragmatic trials are often viewed as extremes or end points on an 
internal-external validity continuum, where efficacy trials have an explanatory 
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purpose used in clinical practice (i.e. a high internal validity is therefore most 
important) and pragmatic trials are used in order to make implementation or 
funding decisions (i.e. generalizability is important) (82).  
Observational studies 
An economic evaluation could also be conducted alongside an observational design 
such as case-control designs, cohorts or cross-section study (82). In observational 
studies, patients receive treatment based on routine decisions made by healthcare 
professionals and no or very few restrictions are made on e.g. selecting patients or 
the activities conducted (82). These studies are essentially real world studies 
investigating “what happens” (or “what happened”) and many applies registers 
either prospectively or retrospectively.  
Observational studies can be used when experimental evaluation is unethical (e.g. 
randomization to abort/not abort is unethical!), impractical (e.g. events occur very 
rarely) or when the evaluators cannot influence how courses of action can be 
allocated for some reason (e.g. lacking the managerial influence to impose 
experiments) (96). Like experimental evaluation, observational studies can compare 
different alternative courses of action (e.g. in case-control designs). Or it can simply 
follow a group of participants without having a control group (single cohort 
designs) (96). 
The main disadvantage of observational studies is the lack of randomization, which 
make it more likely that estimated treatment-effects could be biased or confounded 
(96). At a minimum, statistical adjustment for systematic differences in prognostic 
factors relevant for the treatment-effect must be applied (97); however, this is only 
feasible for observable differences. What randomization ensures is that any 
observable and unobservable imbalances between patients in alternative courses of 
action only exist by chance (96), so this design will have a much higher internal 
validity. If no control group exist at all (e.g. in a single cohort with before/after 
evaluation of costs and outcomes), it is generally considered very difficult to isolate 
a treatment-effect from what would have happened anyway (96).  
2.3.1. CLASSIFICATION OF HEALTH ECONOMIC EVALUATIONS 
Several research designs of economic evaluations could be applied in order to 
evaluate the clinical outcomes and/or costs of healthcare interventions (82). 
Drummond and colleagues distinguishes the characteristics of evaluations used in 
health care decision-making along two dimensions: Firstly, whether the evaluation 
includes a comparison of one or more alternative courses of action and secondly, 
whether the evaluation directly relates costs with a clinical outcome (82). Cost 
descriptions or cost analyses such as cost-of-illness studies (98) and traditional cash 
flow forecasting used in financial management or investment theory (99) are partial 
evaluations, since they either do not include a comparator and/or does not directly 
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relate costs with a clinical outcome (82). Likewise, clinical trials without economic 
analyses are also partial evaluations, since they do not include the costs of 
technologies or relate costs with health outcomes. Full economic evaluation 
includes both a comparison of one or more alternative courses of action and directly 
relates costs with a clinical outcome (82,100). 
There are three basic forms of full economic evaluation, which differs primarily on 
how health-effects are defined and measured (82). In a cost-effectiveness analysis, 
health-effects are measured in natural units, such as years of life gained, number of 
averted incidents or improvement in a pain score (84). The health economic benefit 
of a technology from a cost-effectiveness analysis is therefore expressed as costs 
per unit of effect, e.g. costs per avoided death (82). A limitation of cost-
effectiveness analyses is that they cannot be used to compare health-effects across 
health technologies if outcome measures for assessing the effectiveness of 
alternative technologies are different, e.g. orthopedic surgery in a knee is usually 
not to avoid death (82). So, cost-effectiveness analyses are most useful for 
prioritization within disease groups or within homogenous healthcare programs. 
The cost-utility analysis, in contrast, uses a composite outcome measure for health-
effect in order to compare the effects of technologies across disease groups or 
healthcare programs. Usually, health-effect is measured as QALYs gained or some 
variation of it (e.g. disability-adjusted life years) which is a way of adjusting life 
expectancy for quality of life during the years lived. Results from cost-utility 
analyses are presented as costs per QALYs gained (82). Cost-utility, therefore, have 
a broader appeal and are often viewed as more useful for health care decision-
makers. Cost-benefit analyses values health-effects in monetary units and can 
therefore be used to prioritize technologies across sectors of an economy such as 
between healthcare, transportation and education (82). Cost-benefit analyses also 
allow for the valuation of negative or positive externalities of a health technology 
(82). However, cost-benefit analysis is rarely used due to the absence of market 
prices. 
2.3.2. IMPORTANT DESIGN FEATURES OF HEALTH ECONOMIC 
EVALUATIONS 
Several guidelines for designing, conducting and reporting health economic 
evaluations have been published and can be general recommendations in text books, 
e.g. Drummond and colleagues (82) or general guidelines from societies for health 
economic evaluation (101). There are also specific additional requirements 
depending on the adopted approach, i.e. for decision modeling in health economic 
evaluation (102), trial-based economic evaluation (93) or economic evaluation in 
observational studies (103,104). Looking across these recommendations and 
guidelines several important aspects are important in sound health economic 
evaluations.  
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It is important to describe a well-defined research question that defines the target 
population, the health technologies to be assessed and the objectives of the 
economic evaluation (82,93,101–103). A perspective for the analysis must also be 
described and justified (82,93,101–103). The perspective is the viewpoint from 
which the relevant costs and health-effects are collected (82). The perspective can 
be comprehensive (e.g. a societal perspective or the perspective of the healthcare 
and social sector) or more narrowly scoped (e.g. a specific healthcare provider) 
(82). Choice of courses of action that are compared must be described and justified 
(82,93,101–103). Comparators are the health technology under scrutiny and one or 
more “usual practices” or most effective, least costly or frequent alternative health 
technologies relevant for treatment and care for the target population (82). For 
transparency and to address the potential for generalization, a detailed description 
of all alternatives should be made (82,93,101–103). 
If mortality and health-related quality of life are important outcomes, QALYs 
should be used as outcome (82,93,101–103) and validated instruments should be 
applied (82,93,101–103). Relevant costs categories should reflect the chosen 
perspective as well as measured and valued appropriately (82,93,101–103). The 
first step is to identify resource consumption that can vary between alternative 
health technologies (82). Secondly, the most credible sources for collecting 
resource consumption must be chosen and combined, e.g. from case record forms, 
accounts, cost diaries, questionnaires, registers, time studies, other studies, expert 
opinions etc. (82).  The third step is valuation of the resource consumption (82). 
Ideally, the evaluation should be made based on opportunity costs or market values. 
These would often not exist, so unit valuation is often based on tariffs, average 
salaries or remuneration. From information on resource consumption and unit costs, 
the total costs for each health technology can be calculated (82).     
An appropriate time horizon for the analysis should be chosen (82,93,101–103). 
The choice should ensure that all relevant differences in health effect and costs are 
observable within the evaluation period (82). Health effects and costs occurring 
throughout this period should be discounted in order to reflect a time preference 
assumption and to make interventions with different flows of outcomes and costs 
directly comparable (82,93,101–103).  
An incremental analysis must also be presented, since it is important to examine the 
additional costs and health outcomes that a technology imposes over other 
technologies (82,93,101–103). In health economic evaluation, this is often reflected 
in the incremental cost-effectiveness ratio (ICER), which is the difference in total 
costs between two technologies divided by the difference in health outcome 
between the same two technologies (82).  
Inevitably, any evaluation will contain some form of uncertainty relating to the data 
or the assumption in the evaluation (105). The stochastic uncertainty reflects the 
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variability in costs and health-outcomes demonstrated for seemingly identical 
patients (105). Heterogeneity is concerned with the observed differences in health-
effects and costs between patients that can be explained by observable 
characteristics of those patients (105). Parameter uncertainty reflects assumptions 
made about valuation of specific parameters in the evaluation and structural 
uncertainty is concerned with the analytical choices made (in- and exclusion of 
variables or analysis model) (105).  
The features included in health economic evaluation are therefore manifold, which 
leaves room for many choices of detailed design. Even though recommendations for 
transparent reporting of results from economic evaluations exist, it can still be 
challenging to compare economic evaluations. As a result, some would argue for a 
“reference case” or a preferred choice in the design of an economic evaluation 
based on the features mentioned above in order to make comparisons more reliable 
and transparent (106). According to Gold and colleagues, the societal perspective 
should be chosen, costs should include both cost of health care, patient- and 
caregiver time and productivity loss and a 3% discount rate should be used for 
discounting costs (106). Effectiveness estimates should incorporate both benefits 
and harms, mortality and morbidity should be combined in QALYs and existing 
practice should be a control group (106). Finally, sensitivity analyses should be 
made (at least one-way analyses) and the ICER should be compared with other 
relevant interventions (106). 
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CHAPTER 3. METHODOLOGY 
3.1. A DESCRIPTION OF THE TELECARE NORTH INITIATIVE 
3.1.1. INTERVENTION 
The chosen telehealthcare intervention was supposed to complement or be offered 
in addition to usual practice for monitoring and caring for COPD patients (107). 
The intervention was designed independently of the evaluators.  
The technical part of the telehealthcare solution was a package or “Telekit” (see 
Figure 2) consisting of a standard Samsung Galaxy tablet with an inserted SIM card 
and peripherals capable of measuring and transmitting blood pressure, pulse, blood 
oxygen saturation, and weight. The package also contained a tablet-pen and a user 
manual (108). Each TeleKit was technically prepared in advance. During 
installation at the patient’s home, the Global System for Mobile communications 
(GSM) coverage was checked and in the event of poor coverage, it was possible to 
switch to a local wireless network if this was installed in the home (108).  
Figure 2: A Telekit that consists of a tablet, tablet pen, pulse oximeter, blood pressure monitor and a 
scale. Source: (108).
 
The tablet had two applications (apps) installed: First, a measuring and monitoring 
application containing health-related questions that also could collect and transmit 
the measurements made by the peripherals. From this application, the patient could 
also create an overview over historical measurement values and gain access to a 
message function that allowed for an asynchronously dialogue with a healthcare 
professional. Second, a training-application containing a digital version of the 
manual, several videos showing how the various parts should be used and a training 
video targeted the patient (108). The device was portable but could only be used 
inside Denmark (108). The provided tablet could be updated and managed 
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centrally. Should any of the electronic items in the Telekit display errors, the entire 
TeleKit was usually replaced (108). 
On the receiving end of the measurements conducted via the tablet, health 
professionals from municipalities (usually nurses) could view and evaluate the 
submitted measurements in a web interface (OpenTele). They could only access 
data on patients who were associated with the municipality district they were 
employed in (108). Conducted measurements and answers to disease-specific 
questions were automatically color-coded based on threshold values made in 
advance by the general practitioner for individual patients (108). To facilitate 
COPD patients taking charge over their disease and allow for municipal evaluation 
of monitoring data both groups received disease specific training and training in 
using the device (108). 
The telehealthcare solution offered built upon a previous telehealthcare solution in 
North Denmark Region (109), which required several changes. The new technical 
platform required different software solutions to be developed (e.g. the two 
applications mentioned above) and the measurements were stored and integrated 
with existing information technology (IT) systems throughout the healthcare sector 
(i.e. electronic patient record at the hospitals, care journals in municipalities and 
medical practices throughout the region) to allow for data exchange (108). A 
change of monitoring responsibility from physicians at hospitals and GPs to health 
professionals (primarily nurses) in municipalities was included in TeleCare North. 
This entailed the development of organizational models for monitoring patients and 
implementation of new transitions procedures of patients between sectors (110). 
Particularly health professionals in municipalities would find new types of tasks 
related to overseeing and evaluating monitoring data. In addition, new tasks related 
to the support and instruction in the use of the telehealthcare equipment in the 
patient's home was expected. New tasks for GPs included the formulation, revision 
and reporting of threshold values for various physical indicators of COPD. GPs 
would still be the patients’ primary contact and portal to the healthcare system. 
Health professionals at hospitals would be expected to receive fewer patients for 
admission and outpatient controls thereby reducing their involvement in managing 
COPD patients (110). The COPD patient would be expected to take on an active 
role in managing their own disease and thus responsible for conducting daily 
measurements of physical indicators at home according to a predetermined 
agreement (110). 
The intended target group originally included all COPD patients in North Denmark 
Region “who could potentially benefit from the telehealthcare” (107), which meant 
that patients with all COPD severities could potentially be included in the 
implementation. This also meant that several thousand patients could potentially be 
included. Later on the inclusion criteria was narrowed down a bit to the description 
made in the trial protocol (111).  
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3.1.2. ORGANIZATION OF TELECARE NORTH 
There is no question that TeleCare North was an important initiative for the 
involved stakeholders. It was developed in the geographical area of North Denmark 
Region with the participation of all sectors involved in the management of COPD 
patients. There was a high level of political and management attention and the 
organization surrounding the initiative was large.  
TeleCare North was led by a steering committee consisting of top officials or senior 
members from all of the involved organizations (e.g. the chairwoman of the steering 
committee was the CEO of North Denmark Region and the vice-chairwoman was a 
CEO from Aalborg Municipality, the largest municipality in the region) (107). The 
connection to the national action plan meant that the group of involved stakeholders 
quickly expanded by members of the Danish government (i.e. the Danish Agency 
for Digitalization) and representatives from the Danish Lung Association (107). An 
executive committee was also formed with members from the region, municipalities 
and general practitioners (107). These two committees had three “reference groups” 
that followed the initiative (107). This meant that the project had the attention and 
support of all levels of North Denmark Region, all 11 municipality councils and the 
local branch of the Danish Medical Association (107).  
The task of completing the development and implementation of the telehealthcare 
intervention was given to a newly formed region-based secretariat solely dedicated 
to the initiative (107). This secretariat reported directly to the steering committee 
and the CEO of North Denmark Region (107). The secretariat became responsible 
for revising the IT-solution, revising how data was stored and evaluated, changing 
the responsibility for monitoring and the frequency of monitoring COPD patients 
and adjusting the content of work for particularly healthcare professionals in 
municipalities (108). The secretariat split these tasks into four main “tracks” each 
with its own project organization (108): An IT track focused on the technical 
elements and integration and coordination with national stakeholders who focused 
on the future telehealthcare technical infrastructure. An organization track focused 
on establishing coherent cross-sectorial work procedures and managed potential 
legal challenges. A clinical track focused on clarification of roles in delivering 
healthcare services, the content of the clinical work and patient pathways. Finally, 
an implementation track coordinated and supported the local implementation across 
all municipalities and hospitals (107). 
The responsibility for evaluating the TeleCare North initiative was divided between 
three professors from three different departments at Aalborg University and they all 
had a seat in the steering committee, where they decided on the overall research 
design for the evaluation. The task of designing a detailed evaluation and for 
completing those evaluations was then given to three more or less separate Ph.D.-
stipends under the supervision of the professors. The general purpose of evaluation 
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was to generate quantitative and qualitative evidence of the effects of the initiative 
and for future implementation of telehealthcare in Denmark in accordance with the 
national action plan (112). A Ph.D.-student from the Department of Health Science 
and Technology focused on “patient-related” outcomes such as health-related 
quality of life, mortality, lung function, blood pressure and pulse. (112). A Ph.D.-
student from the Department of Sociology and Social Work concentrated on the 
management- and organizational implications in preparing for and operating a 
large-scale implementation of telehealthcare (112). Finally, a Ph.D.-student from 
the Department of Business and Management (the author of this PhD thesis), were 
given the responsibility of conducting a health economic evaluation of the TeleCare 
North initiative (112).  
3.1.3. THE DANISH “NATIONAL ACTION PLAN FOR DISSEMINATION 
OF TELEMEDICINE” 
TeleCare North had a connection to a national action plan meant to ensure an 
evidence-based foundation for a later decision on whether or not to implement 
certain telehealthcare initiatives to particular patient groups in Denmark (107). This 
decision took place in late 2015 (113).  
In June 2012, the Danish government had published “The national action plan for 
dissemination of telemedicine” (33), which was also agreed upon by “Local 
Government Denmark” and “Danish Regions”, interest organizations for the 98 
Danish municipalities and the five Danish regions, respectively. The action plan 
was meant to ensure that new and more ambitious telehealthcare initiatives were 
tested and that already effective telehealthcare initiatives would be applied to a 
greater extent (33). The action plan also entailed conducting evaluations, which was 
important in order to facilitate a later national decision of which telehealthcare 
solutions should be disseminated and to which patient-groups (33). The action plan 
was complemented by £8 million dedicated to co-fund five telehealthcare projects 
across the country (33). The five telehealthcare initiatives were selected based on 
the scale of the initiative, i.e. the number of patients or number of 
regions/municipalities included, a positive economic business case, that the 
initiatives supported integrative patient pathways and that the initiatives had strong 
local support (33). Two initiatives were small demonstration projects on previously 
uninvestigated disease areas (mental illness) and one initiative was a further 
dissemination of an already effective telehealthcare solution (for diabetes) (33).  
Most relevant for this thesis, the action plan also consisted of two large-scale 
implementation projects with evaluations of the effects of these implementations – 
one of which was TeleCare North. The two initiatives should in general seek to 
coordinate and establish a generic IT infrastructure that supported home monitoring 
and video consultations nationally that could also be opened up to other patient-
groups in the longer run. 
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The total budget for implementing TeleCare North was roughly £5 million and in 
addition to the funds made available in “the national action plan for dissemination 
of telemedicine” also included funds from the Obel Family Foundation, the 
European Social Fund as well as local partners in North Denmark Region (107). 
The quantifiable objectives of TeleCare North was to increase the health-related 
quality of life of COPD patients thereby increasing their quality-adjusted life years 
(QALYs), to reduce the number of hospital contacts and the amount of time spent 
in municipalities on home care (33,114). Furthermore, several “qualitative” effects 
were expected, e.g. better coordinated patient pathways and increasing self-
management skills for patients (33,114).   
The second large-scale initiative part of the action plan was “Clinically Integrated 
Home Monitoring”; Danish acronym “KIH”) (33). It was implemented in two 
Danish regions (the Capital Region and Central Denmark Region) and would use a 
slightly different technical solution and organizational setup to monitor an 
estimated 2,000 patients (actual inclusion app. 1,200 patients (115)) from five 
different patient groups (diabetes, COPD, pregnant women with or without 
complications and patients with gastro-intestinal inflammation) in their own home 
(33). The objectives were across initiatives in KIH to reduce the number and 
duration of hospital admissions and outpatient control visits. In addition, a planned 
task-shifting from physicians to nurses should free up specialized resources. 
Finally, a number of “qualitative” effects were expected (e.g. correct and consistent 
treatment across sectors while strengthening patients' skills and empowerment) 
(33). The total budget of KIH was £6.6 million (116). 
The five initiatives in KIH consisted of different evaluation designs; two were 
based on randomized trials and three were cohort designs. The economic analysis of 
resource consumption in the health care and social sector for all initiatives were 
based on before/after time studies of health professions involved in outpatient visits, 
admissions and municipality based social services or their professional estimates of 
time consumption (115). This time consumption was valued based on annual 
average salaries for the involved professions (108). The sub-project focusing on 
telehealthcare for COPD patients that are most relevant in comparison with 
TeleCare North were one of the two randomized trial with 281 participants (140 
received telehealthcare) with severe COPD (108). This study focused specifically 
on time consumption for telehealthcare, hospital admissions, outpatient visits and 
patient transport time for hospital visits. Time consumption for personal care at 
home and home nursing care were also included, but only as a sample over a three 
to four week period (108).    
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3.2. RESEARCH DESIGN FOR RQ1: THE EFFECTIVENESS AND 
COST-EFFECTIVENESS OF TELECARE NORTH 
The research design is described in the trial protocol (article 2 in appendix 2), so 
this paragraph therefore consists of a summary of this article and the conclusions 
from the systematic review (article 1 in appendix 1) that lead to the design of 
particularly the trial-based economic evaluation of TeleCare North.  
3.2.1. SUMMARY OF THE SYSTEMATIC REVIEW (ARTICLE 1) 
Title: A systematic review of the cost and cost-effectiveness of telehealthcare to 
patients suffering from chronic obstructive pulmonary disease (117). 
Objectives: To conduct a systematic review of the evidence on the costs and cost-
effectiveness of telehealthcare for patients with COPD. This could be used to assess 
the number and quality of the current evidence of costs and cost-effectiveness of 
telehealthcare and to inform the design of future evaluations. 
Methods: A systematic literature search was conducted within 8 scientific 
databases complemented by a search for grey literature in Google Scholar. Studies 
should include primary data on cost or cost-effectiveness specifically for COPD 
patients, have applied technologies similar to the definition of the latest Cochrane 
review on effectiveness of telehealthcare to COPD patients, and only one study 
from the same trial could be included. No exclusion was made based on language 
and publication date. Studies fulfilling these inclusion and exclusion criteria were 
then critically appraised by applying the Consensus Health Economic Criteria list 
for assessing the methodological quality of economic evaluations. 
Results: Only six studies were identified with the inclusion- and exclusion criteria 
used in the review. These studies were conducted in Europe and North America and 
involved a total of 559 COPD patients whereof 281 had received telehealthcare. 
Although all included studies demonstrate a potential for cost savings for primarily 
patients with severe and very severe COPD, only one of these studies is a cost-
effectiveness study whereas the other five are cost studies only. The telehealthcare 
interventions are also very heterogeneous and the activities in their comparator 
“usual care” are difficult to identify. Furthermore, the studies have relatively 
narrow cost-scopes or perspectives which mean that the identified cost savings in 
hospitals are at risk of merely being transferred to other healthcare delivery sectors 
(e.g. general practitioners or communities). Finally, the studies were efficacy trials 
that included a small number of patients and have relatively short follow-up period. 
The quality of the evidence was poor. Five of these studies were deemed as having 
“low quality” and one study was assessed as “moderate quality” in its economic 
evaluation design.
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Discussion: The review demonstrated a potential for cost savings mainly to 
hospitals and/or the healthcare sector when telehealthcare is applied to COPD 
patients. However, we argued that decision-makers should be skeptical of the 
current evidence of cost-effectiveness in telehealthcare research. Several 
improvements to future research were deemed necessary, e.g. more cost-utility 
analyses that relate costs to QALYs should be conducted; these studies should also 
have broader cost-scopes and longer follow-up periods and finally larger studies 
should be conducted to allow for heterogeneity analyses.  
3.2.2. SUMMARY OF THE TRIAL PROTOCOL (ARTICLE 2) 
Title: Effectiveness and cost-effectiveness of telehealthcare for chronic obstructive 
pulmonary disease: study protocol for a cluster randomized controlled trial (111).
Building on the call for more research in previously conducted systematic reviews 
of telehealthcare for COPD patients and the systematic review from article 1, two 
departments collaborated on designing a clinical trial together in order to estimate 
the effectiveness and cost-effectiveness of the TeleCare North initiative.  
Objectives: To describe the design of a pragmatic cluster-randomized trial with 
nested economic evaluation. The study is meant to assess the effectiveness and the 
cost-effectiveness of the Danish TeleCare North telehealthcare solution for patients 
suffering from COPD compared to usual practice implemented throughout North 
Denmark Region in 2014-2015.  
Methods: North Denmark Region and 10 out of 11 municipalities participated in 
the trial and all general practitioners were invited to participate. Spirometry- 
diagnosed COPD patients were eligible for inclusion if they received treatment 
according to GOLD-guidelines, if COPD was a primary disease and if they met a 
set of additional in- and exclusion criteria (MRC and CAT score, residence, 
language and GSM coverage). Patients were recruited by general practitioners. 26 
municipality districts (13 pairs) defined randomization units to reduce the risk of 
contamination. Assessment was divided into an effectiveness theme and a cost-
effectiveness theme. The primary effectiveness outcome was differences in health-
related quality of life measured by Short-Form 36 (SF-36) from baseline to 12 
months follow-up. Secondary effectiveness outcomes were changes in mortality and 
physiological parameters from baseline to the follow-up at 12 months. The cost-
effectiveness outcome was the incremental cost-effectiveness ratio measured as the 
cost per QALY gained from baseline to follow-up at 12 months. 
 
Discussion: The study was designed to answer the call for more comparative 
research with nested economic evaluation of large-scale implementation of 
telehealthcare to COPD patients. It does so by including an estimated 1,200 patients 
and has a relatively broad cost-scope. The duration of 12 months might be too short 
to capture all relevant evidence of costs and effects; however, for practical and 
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ethical reasons, the involved stakeholders decided that all eligible patients should be 
able to option for the telehealthcare intervention no later than 12 months after 
randomization.  
3.3. RESEARCH DESIGN FOR RQ2: APPLICATION OF 
EVIDENCE IN THE NATIONAL DECISION  
The research design for RQ2 is rooted in the qualitative research paradigm, which 
could be defined as "any kind of research that produces findings not arrived at by 
means of statistical procedures or other means of quantification" (118, p17). The 
paradigm seeks to shed light on, understand or to create theoretical or 
methodological lessons for future reference in similar situations, which is very 
different from quantitative research aimed at prediction and generalization of results 
(119). Qualitative research is an investigative process where a researcher seeks to 
make sense of a phenomenon (whether cognitive or social) (120) and has strong 
foundations in fields such as sociology and political science (120).  
Qualitative research has several important characteristics (119): it is conducted in a 
“natural setting” outside the control of the researcher (e.g. where actual events take 
place) (120). The researcher is the primary instrument for interpreting data in a 
process of selecting, examining and analyzing the applied data (119,120). Usually, 
several data sources and -methods are applied such as documents, observations or 
interviews (119,120). Results are reported as descriptive data in quotations or 
pictures (119,120). Furthermore, qualitative research focuses on the events and 
outcomes as the occurred (119,120). Finally, it is important that the researcher 
reflects on the role he or she has in the interpretation of the data and conclusions 
drawn (119,120). 
This research design is meant as a carrier to allow for investigation of how a 
national decision on telehealthcare unfolded. As an inductive research paradigm, 
qualitative research could also facilitate theory-building that could be incorporated 
in future research on cost-effectiveness methods for telehealthcare. As such, this 
investigation seeks to illuminate how a national resource allocation unfolded and 
seek to fertilize the ground for an analytical generalization of the lessons learned 
that could be used to increase the usefulness of future evaluation of the economic 
effects of telehealthcare.   
3.3.1. DATA COLLECTION STRATEGY 
Research question two was defined ex post as part of an after-reflection of the 
national decision-making context of telehealthcare in Denmark, i.e. after the 
primary data collection for TeleCare North had ended, data for the trial were 
analyzed, results presented and the Ph.D thesis initiated. Therefore, feasible 
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research designs to choose from in answering this question was limited. The choice 
fell on document analysis, which according to Bowen can be defined as “a
procedure for reviewing or evaluating documents” (121, p27), such as agendas, 
letters, press releases, institutional reports, event programs, web pages, newspaper 
clippings and –articles (121).  
Document analysis can also be used as a “stand-alone” method for specific 
purposes (121). Examples includes tracking changes and development in the 
formulation of reports or bills or to analyze changes in descriptions of initiatives or 
projects over time (121) as well as the examination of document usage by certain 
people or organizations (121). Document analysis can also be used to generate new 
questions that needs to be addressed in research (121). Document analysis is 
generally thought of as an efficient research method for these purposes, since it 
involves data selection and not data collection and can be a preferred or necessary 
choice when collection of new data is unfeasible (121).  
3.3.2. BOUNDING THE STUDY 
Selection of documents is not based on random sampling; rather documents are 
purposefully selected in order to help the researcher understand the problem (119). 
This selection is based on four criteria (122): 1) the setting, i.e. where research 
could take place 2) the actors, i.e. from whom data could be collected, 3) the events, 
i.e. what pre-planned situations data could be collected from 4) and the process, i.e. 
how events actually unfolded (120).  
The chosen setting is publically available documents from researchers and 
institutions involved in creating evidence on the effectiveness and cost-
effectiveness of telehealthcare solutions (e.g. research articles and reports published 
within the national action plan). In addition, publically available documents from 
decision-stakeholders participating in the national decision or debate on whether or 
not to disseminate telehealthcare solutions to certain patients based on the national 
action plan (e.g. web pages and newspaper clippings).  
Relevant actors are the Danish Ministry of Health, the Danish Regions and Local 
Government Denmark, the Danish Agency for Digitalization, PA Consulting Group 
and researchers from Denmark affiliated with TeleCare North and KIH as well as 
international researchers generating new evidence since the formulation of the 
action plan in 2012. The Danish Ministry of Health, Danish Regions and Local 
Government Denmark was responsible for agreeing to create and fund a national 
action plan and for making the decision to disseminate telehealthcare to certain 
patient groups. A national steering committee with representatives from the five 
Danish regions, 98 municipalities, the Ministry of Health and the Danish Agency 
for Digitalisation has since been responsible for implementing and communicating 
this national dissemination. Researchers have since 2012 and up to the decision in 
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autumn 2015 published evidence on the effectiveness, costs and cost-effectiveness 
of telehealthcare solutions both outside and within the national action plan 
especially two widely cited international studies (Telescot in Scotland and Whole 
System Demonstrator in England). PA Consulting Group was responsible for 
conducting an initial and revised national business case based on available 
evidence. Prominent health economist and other researchers within telehealthcare 
took part in the debate as it unfolded.  
The “events” include the content of the Danish “national action plan for the 
dissemination of telemedicine” including the data and data-sources it applied. But 
also the new evidence that was generated internationally and nationally from 
January 2013 up to the national decision that could potentially be part of the 
evidence used in the national decision in autumn 2015. The events also include the 
actual decision taken and the premises for this decision. This is complemented by 
the process as it unfolded, particularly a debate that occurred in the media in April 
and May 2016 on business cases and economic methodology used in the decision.    
For this research question, the following central documents are therefore selected 
(Table 3). 
Table 3: Overview of documents selected for analysis of evidence application in national decision. 
Source: Own contribution. 
Document Rationale 
“The national action plan for the dissemination of 
telemedicine” (33) 
Contains the initial expectations from the Danish 
government, Danish regions and municipalities 
for the effects and costs of telehealthcare 
and the types of evidence used nationally. But it 
also gives a sense on how evidence synthesis 
methodologically was created nationally. 
Initial business case for TeleCare North (114) Contains the initial expectations from North 
Denmark Region and are used to formulate the 
“national action for dissemination of 
telemedicine” 
International scientific studies on telehealthcare 
for COPD patients published after the initiation of 
the action plan, especially 
Whole system demonstrator project 
(WSD) in England (123–126) 
Telescot in Scotland (127,128)
Important new evidence and methodology that 
could in principle be incorporated into the 
decision 
Empirical results from initiatives funded by the 
“The national action plan for the dissemination of 
telemedicine” 
Systematic review made by CIMT 
Contains new evidence directly associated with 
the decision to implement telehealthcare. It also 
includes an assessment of the quality of existing 
evidence that could have provided background to 
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(25)
Final report from “Clinically 
Integrated home monitoring (KIH)” 
(115)
Final report from TeleCare North 
(108)
Research articles from TeleCare North 
(117,129–131)
the formulation of the action plan. 
 
National business cases on the economic effects 
of disseminating telehealthcare in Denmark 
Initial business case (132)
Important analyses to assess the expected impact 
the different sectors involved in managing COPD 
had in Denmark over time. Results from the 
business cases would have a huge impact on the 
Government, regions’ and municipalities’ desire 
to implement the telehealthcare solution. 
Web pages of the Danish Agency for 
Digitalization (113,133–138) 
Communication platform for the dissemination of 
telehealthcare in Denmark 
Altinget.dk  panel debate on the initiatives in  
“The national action plan for the dissemination of 
telemedicine” (139–157) 
 
Became an important source for assessing the 
relevance, balance and wording of different 
stakeholders on the results from the action plan as 
events unfolded. Also source of input to how 
stakeholders perceived the research designs used. 
Magazine clippings on the national decision 
(158,159) 
Became an important source for assessing the 
relevance, balance and wording of different 
stakeholders on the results from the action plan as 
events unfolded. Also source of input to how 
stakeholders perceived the research designs used. 
3.3.3. PROCEDURE FOR THE ANALYSIS 
As with most qualitative methods, the analytical strategy in document analysis is an 
iterative process of reading, categorization topics, formulating themes and 
interpretation (119,120). There are several analytical steps to undertake and they 
could look slightly different depending on the employed text-book, but the general 
procedure is this (119,120): First, the data for analysis are organized and prepared, 
e.g. by printing or transcribing documents and then sorted depending on the type 
and source of the document (119–121). Second, all documents are read and for each 
document, the researcher elicit the overall meaning or message of the document 
(119–121). Third, for each document, the researcher start coding the text (119–
121). Fourth, this coding process are used to synthesize categories into a smaller 
and more abstract set of themes that could later serve as the main findings from the 
analysis (119–121). The themes should look across documents and be supported by 
multiple sources (119–121). Fifth, the researcher applies his or her personal 
interpretation from an understanding that is brought to the study from past 
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experiences or the literature (119–121). These steps are iterative in the sense that 
data will be continuously reviewed and repeatedly coded until “data saturation”, 
where no more major themes can be elicited from the texts by the researcher.  
Finally, the interpretations made from the analysis should undergo a process of 
verification, ideally based on several strategies, such as triangulation of methods, a 
hearing process with the involved decision-stakeholders or a prolonged data 
collection with repeated analyses, participating in and checking all steps in the 
analysis process and by reflecting over and stating the role of the researcher (119–
121). 
The documents selected for this analysis were printed out on paper and organized 
into the groupings made in Table 3 and the researcher’s initial thoughts on the 
meaning of each document were noted on the top of document. The documents in 
each grouping were arranged in piles. Then hand-coding commenced for each 
document by highlighting certain passages and writing a representative word or 
category for this passage in the margin. When all documents for each grouping 
were read, major themes were created on post-it notes and attached to their 
respective piles. More than one theme could be created per pile. All of this was 
combined by the researcher’s personal experience in the past, the theoretical 
literature on resource allocation in health policy and employed methodology used 
within health economic science. Finally, the researcher went back to each document 
to look for additional categories or themes inspired by the generated themes within 
each grouping of documents as well as the literature and personal experience.  
3.3.4. RESEARCHER’S ROLE 
To allow the reader to evaluate the credibility in the accounts made, a verification is 
made based on a single strategy, where the researcher declare any position and 
worldview that could affect the description and interpretation of the results 
conducted (119). Seeking to become a health economist and being the 
corresponding author of the trial-based economic evaluation of TeleCare North, I 
am obviously not a neutral bystander in the national decision. I am prone to accept 
and recommend the methodology and reporting standards that are developed for 
health care resource allocation and health economic evaluation. Therefore, I can 
recognize and agree on much of the criticism that there has been of the national 
decision process which came from health economists in particular. But I also have 
some insights into some of the reasoning behind these decisions that were 
unavailable to those critics. 
I have no position on the level of treatment and care for COPD patients in Denmark 
or if telehealthcare as opposed to other technologies should be adopted. I would 
prefer that only cost-effective technologies are disseminated, but recognize that this 
would ultimately depend on other rationales than technical efficiency, how certain 
decision-makers would like to be and how much they are willing to spend to 
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achieve effects. I also acknowledge that no evaluation can answer all questions that 
decision-makers might have. 
I did not know any of the stakeholders personally prior to the TeleCare North 
evaluation, but have had a close contact with representatives from North Denmark 
Region, the municipalities based here, government and the health economists that 
have criticized the national decision process throughout the study. I also have past 
experience with the same sort of research problem and stakeholders by being part of 
the Danish HTA evaluation milieu prior to becoming a Ph.D. student and have 
some experience with how decision processes are and can be in Denmark. 
I have some experience with conducting and reporting scientific mixed methods 
studies in health informatics, e.g. (160,161) and have respect for the merits of 
qualitative research methodology, although conducting qualitative studies is not my 
main skill. In being part of mixed methods research, I have often been struck by 
how dogmatic both quantitative and qualitative researchers can be in insisting that 
their approach are the only right way to answer a research question instead of 
recognizing the relative strengths and weaknesses of each methodology. 
My intention with describing and commenting the national decision process is not 
to put anyone on display or pass judgment. Rather it is to become an “active 
listener” in order to gain insight into decision-making in order to inform future 
economic research in telehealthcare. 
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CHAPTER 4. THE EFFECTIVENESS 
AND COST-EFFECTIVENESS OF THE 
TELECARE NORTH TRIAL
The research question posed was: “Is the chosen telehealthcare solution for COPD 
patients adopted in the TeleCare North trial effective and cost-effective?” The 
intention was to answer a call for more comparative research on the effectiveness 
and particularly the cost-effectiveness of telehealthcare to COPD patients. This 
research agenda is sought answered by three main publications presented in 
appendices 3-5. A short summary of the contents of the articles is provided in this 
chapter.  
4.1. SUMMARY OF THE EFFECTIVENESS EVALUATION 
(ARTICLE 3) 
Title: Telehealthcare for patients suffering from COPD: Effects on health-related 
quality of life - Results from the Danish “TeleCare North” cluster-randomised trial
(131). 
Objectives: To assess the within-trial effectiveness of telehealthcare compared with 
usual practice for patients with COPD.   
Methods: The main outcome of telehealthcare was assessed by following 1,225 
COPD patients (578 in intervention group; 647 in control group) for 12 months and 
having their health-related quality of life measured and compared by the Short-
Form 36 (SF-36). The study applied an intention-to-treat principle (162), multiple 
imputation, good practices for reporting clinical trials extended to CRTs (91,163) 
and multilevel methods in accordance with methodology guidelines for cluster-
randomized trials (164,165). Data for this analysis stemmed from paper-
questionnaires sent to patients (health-related quality of life and socio-demographic 
characteristics) and measurements of physiological indicators made within the 
office of the patients’ GP. Statistical analysis was performed by two separate linear 
mixed models for continuous outcomes for the mean differences in PCS and MCS 
scores between groups adjusting for treatment arm, respective baseline PDC or 
MCS scores, age, gender, baseline forced expiratory volume in one second 
(FEV1%), marital status, diabetes status, cancer status, and clustering.  
Results: Contrary to expectations, the TeleCare North cluster-randomized trial 
demonstrated no difference in health-related quality of life measured by SF-36. The 
adjusted mean differences in HRQoL from baseline to the 12-month follow-up were 
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for PCS: 0.1399 (95% CI, -1.3689; 1.6496) and for MCS: 0.3603 (95% CI, -1.6788; 
2.3994). Although, a tendency for a slower deterioration in COPD patients’ health-
related quality of life in general and for some subgroups were detected, these were 
not statistically significant either.  
Discussion: This study is one of the largest effectiveness studies on telehealthcare 
in the world and the first large-scale evaluation in Denmark. Based on previous 
experiences with telehealthcare in North Denmark Region, this study sought to 
strengthen implementation by ensuring that patients had user-friendly telehealthcare 
equipment and by gearing the delivery organizations more to respond to reported 
physical indicators to prevent COPD exacerbations. Still no statistically significant 
effects on health-related quality of life were detected. Potential reasons include the 
Hawthorne effect that could have influence the control group; that we have 
somehow missed important covariates explaining differences in health-related 
quality of life; that the instrument SF-36 was not sufficiently sensitive to detect 
outcome differences in patients with COPD or if health-related quality of life is the 
most relevant effectiveness measure in a hierarchy of outcome measures. Future 
experimental research should therefore be directed to identifying important 
mechanisms leading to specific outcomes with the help of qualitative research.
4.2. SUMMARY OF THE MAIN COST-EFFECTIVENESS 
RESULTS (ARTICLE 4) 
Title: Cost-effectiveness of telehealthcare to patients with chronic obstructive 
pulmonary disease: Results from the Danish “TeleCare North” cluster-randomized 
trial (129). 
Objectives: To report the within-trial cost-effectiveness of a telehealthcare solution 
in addition to usual care compared with usual care for all participants included in 
the trial.  
Methods: The trial-based economic evaluation was designed as a 12 months cost-
utility analysis alongside a CRT with a healthcare- and social sector perspective. 
Incremental total cost per QALY gained was the main outcome. The study applied 
an intention-to-treat principle (162), multiple imputation, good practices for 
reporting economic evaluations alongside clinical trials (166) and multilevel 
methods in accordance with methodology guidelines for cluster-randomized trials 
(164,165) and for economic evaluation of cluster-randomized trials (167). Data for 
the economic evaluation came from national registers (resource consumption in 
hospitals, GPs offices and medicine), care journals (resource consumption in 
municipalities) as well as questionnaires sent to patients (health-related quality of 
life and socio-demographic characteristics) and measurements of physiological 
indicators made within the office of the patients’ GP at baseline (111,129,130). 
Estimation of treatment effects was based on two separate linear mixed effects 
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models to allow for different covariates. Total costs were adjusted for treatment 
arm, baseline EQ5D score, baseline costs, age, baseline FEV1%, presence of 
musculoskeletal disease and clustering. QALYs gained were adjusted for treatment 
group, baseline EQ5D score, age, gender, baseline FEV1%, marital status, presence 
of diabetes, presence of cancer and clustering. A deterministic ICER-estimate was 
calculated via the treatment effects outputs from both models. Uncertainty 
surrounding cost-effectiveness was quantified by exporting the outputs from the 
multilevel models along with Cholesky’s decomposition matrix to a Monte Carlo 
simulation program developed in Microsoft Excel. Redrawing 5,000 new parameter 
estimates from the estimated treatment-effects with its standard errors, new 
estimates of incremental QALYs and incremental total costs were calculated to 
construct cost-effectiveness acceptability curves. Three one-way sensitivity 
analyses was also conducted: One focused on assessing the effects of a different 
definition of what constituted a relevant hospital admission; a second on effects of 
reduced procurement prices and scale of the trial; a third on learning curve effects 
in monitoring, i.e. reduced monitoring time. 
Results: The adjusted mean difference in total costs between telehealthcare and 
usual care was €728 (95% CI: -754; 2211) from a health- and social sector 
perspective. The adjusted mean difference in QALYs gained was 0.0132 (95% CI: -
0.0083; 0.0346). This lead to a deterministic ICER estimate of €55,327 per QALY 
gained. Without a willingness-to-pay (WTP) threshold value, decision-makers 
should be willing to pay more than €55,000 to achieve a probability of cost-
effectiveness greater than 50%. This conclusion is robust to changes in the 
definition of hospital contacts and reduced intervention costs. Only in the most 
optimistic scenario combining the effects of all sensitivity analyses, does the 
incremental cost-effectiveness ratio fall below UK thresholds values (€21,068 per 
quality-adjusted life-year). The telehealthcare solution is therefore unlikely to be 
cost-effective for all included COPD patients. 
Discussion: This study was a large-scale pragmatic randomized trial with 
embedded cost-utility analysis that has been requested by systematic reviewers in 
order to improve the current evidence base on the cost-effectiveness of 
telehealthcare. A relatively broad health care and social sector perspective was 
chosen and the cost-analyses of resource use are based on register data. The way 
telehealthcare was implemented may have affected cost-effectiveness, e.g. because 
involved organizations and healthcare professionals had to find new ways of 
working together after implementation of the telehealthcare solution and adapt to 
new work procedures which could have affected resource consumption. The target 
COPD population might also have proven too broad, e.g. included participants 
presumably had stable COPD across all severities at recruitment and it is unknown 
if inclusion of patients with more acute COPD would have improved cost-
effectiveness. 
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4.3. SUMMARY OF THE HETEROGENEITY ANALYSIS OF COST-
EFFECTIVENESS (ARTICLE 5) 
Title: Heterogeneity analysis of telehealthcare to patients with chronic obstructive 
pulmonary disease: The case of the Danish “TeleCare North” cluster-randomized 
trial (130). 
Objectives: To explore sources of heterogeneity in cost-effectiveness for patients 
with COPD. 
Methods: The analysis utilized the same design, data sources, reporting standards 
and methodology as the main cost-utility analysis. The only difference is that it 
focused on treatment-by-covariate interactions in order to make conclusions about 
certain patient subgroups. Six subgroups were analyzed post hoc which focused on 
differences in cost-effectiveness across the severities of COPD, differences in the 
presence of a set of comorbidities, and differences in cost-effectiveness across age-
groups, gender, resource patterns (resource use in social care sector prior to 
randomization) and monitoring site.
Results: Results indicate that existing resource patterns of patients and variations in 
delivery site practices might have a strong influence on cost-effectiveness, possibly 
stronger than the included health or socio-demographic sources of heterogeneity. 
Across COPD severities measured as GOLD1-4, the highest probability of cost-
effectiveness was achieved for severe COPD (GOLD3) (68% at a WTP threshold of 
€25,000 and 70% at €40,000). At the same time, the probabilities that other COPD 
severities are cost-effective remain low (between 33-44%). This result seems to 
indicate that previous cost-effectiveness research identified in the systematic review 
(article 1) have (inadvertently) chosen the most cost-effective patients for cost-
analysis which can explain why a potential for cost-effectiveness and lower costs 
have been demonstrated for telehealthcare previously. This would not generally be 
the case across COPD patients. Similarly, telehealthcare to patients younger than 60 
years might be more likely to be cost-effective than older COPD patients. No firm 
conclusions could be made of the included comorbidities and gender. 
Discussion: There is almost no existing knowledge of sources of heterogeneity in 
cost-effectiveness for COPD patients in telehealthcare research. This study has 
sought post hoc to nuance the available evidence by presenting incremental costs, 
incremental QALYs and the uncertainty around these estimates in a set of 
subgroups from a trial-based economic evaluation. A limitation of the study is that 
the statistical power is insufficient to conclude that the differences found is no more 
than random noise in the data, but as long as the analyses are exploratory, they 
could be used to inform future research designs. It is recommended that much more 
focus should be on how context and implementation affects the cost-effectiveness 
of telehealthcare, e.g. by integrating formative evaluation into economic evaluation. 
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CHAPTER 5. APPLICATION OF 
EVIDENCE IN THE NATIONAL 
DECISION
The research question posed was: “How was evidence applied in a national Danish 
decision-making context of whether or not to adopt telehealthcare?”. The intention 
is to place the results from TeleCare North into a national resource allocation 
context by providing a first-hand empirical account, as opposed to yet another 
theoretical examination, of the usefulness of economic evaluation in decision-
making. Along with a theoretical standpoint in health economics and the 
experiences gained with the design and conduct of TeleCare North, the intention is 
to illustrate dilemmas with the current approach to health economic evaluation and 
also draw out themes that can be used to build additional theory on economic 
evaluation of telehealthcare. 
5.1. THE DECISION 
Although not published scientifically yet, the results from the economic evaluation 
of TeleCare North (results from article 4 and 5) were presented to the steering 
committee of TeleCare North in August 2015. In October 2015, these results 
became part of the annual financial agreement for 2016 between the Danish 
Government, “Danish Regions” and “Local Government Denmark” whereby 
telehealthcare should be disseminated to “relevant” COPD patients (originally 
described as patients with severe COPD, GOLD 3 (135)) throughout Denmark 
(168). Six months later, in March 2016, the Danish Agency for Digitalization 
presented an implementation plan (134), in which it became up to each region and 
the municipalities in the regions’ geographical area to locally implement the 
solution (134). It was also decided to continue developing the IT-infrastructure 
from KIH and TeleCare North and to test the telehealthcare intervention on new 
patient groups (113).  
5.2. METHODOLOGICAL APPROACH 
The methodology used to synthesize the available evidence and support the national 
decision followed the principles and guidelines of the Danish Government’s 
business case model (132,136) designed for government IT-projects that are subject 
to state accounting rules. In general, business case methodology rests on investment 
theory, but little scientific literature specific to the design and conduct of business 
cases exist (i.e. few scientific journals publishes business case results and 
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methodology). Instead, some books and other material can be found from 
consultancy agencies and other institutions that agitate for and describe business 
cases to be used for corporate decision-support, e.g. (169,170). In practice, a 
business case become associated with investment decisions, where the net present 
value of expected future cash flows (income and expenses) is analyzed for a given 
investment and potentially put into a strategic market context for the company 
considering making the investment. The Business Case Guide for example (170) is 
an attempt to describe the content of business cases and divides these into five 
sections: An introduction containing a summary of the business case, criteria for 
evaluation (net present value or some other criterion) and time horizon for the 
analysis (170). A methodology section should contain the boundaries for the study 
(geographical, organizational or other), major assumptions underlying inputs to the 
analysis as well as the model for calculating income and expenses (170). A results 
section should include a detailed description of the elements used in the cash flow 
calculation and potential not-quantifiable effects can be described and justified as 
well (170). A risk assessment including sensitivity analysis typically involving 
changed assumptions of input parameters or changing strategic assumptions (e.g. 
market growth, competitor or supplier behavior, inflation) can be carried out using 
simple techniques or more advanced simulations (170). Finally, the main 
conclusions should be stated and often several specific recommendations are 
described (170). 
Most of these business case principles can also be found in the Danish 
Government’s business case model, that also applies to single studies (136). In 
addition to a similar build-up of the report, three principles are described in the 
guidelines for designing an reporting the business case model (136). First, the 
business case model generally relies on expense-analyses based on before and after 
studies with help of a “program model” (a program theory describing as-is and to-
be work flows and organization) (136). The current operating situation must be 
described and an assessment made of current expenses involved in performing the 
tasks that the new program seeks to influence (as-is situation). Thereafter, a 
quantification of estimated development/implementation expenses is required. Two 
future operational situations (i.e. to-be scenarios) must be described and estimated: 
A “0-scenario”, describing what would likely happen if the program is not 
implemented along with estimated expenses associated with this scenario. A “1-
scenario” describing the program and likely effects if the program is implemented 
should also be included. For all as-is and to-be situations, effects should be 
quantifiable, but there is room for reporting “non-economic” effects separately 
(136). Economic effects can only be included if they can be accrued and realized by 
public institutions, i.e. be factored into a specific public account (136). Second, 
cash flows should be described in detail as should data sources and input values. 
Third, any risks must be described as should at least two sensitivity analyses (a 
worst case and best case scenario) (136). After evaluation initiation, the business 
case can be updated in order to manage and regulate expenses (136).  
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The Government’s business case model was used as a funding format for the 
initiatives in the action plan and it was initially required that all initiatives should 
continue with this format in their subsequent economic evaluations in order to 
update the business cases with empirical results from each initiative. The KIH 
initiative continued with the business case format and chose to focus on a labor 
saving variant of it (115) by applying a program model to describe current and 
future work flows for health professionals in municipalities and particularly for 
health professionals involved in hospital admissions and outpatient visits (115). The 
evaluation of TeleCare North was the only initiative where results should be 
published scientifically. Building on the call for more comparative research of 
telehealthcare and a trial-based economic evaluation of a pilot trial, it was decided 
to seek to continue with this evaluation format for TeleCare North. So, the changed 
design for the economic evaluation was a particular focus prior to the 
implementation of TeleCare North and after some debate, it was accepted that 
TeleCare North deviated from the business case format. The compromise became 
that the results from the trial-based economic evaluation should be “translated” to 
the business case format by the Ph.D.-student and handed over to a consultancy 
agency in aggregated form in order for them to calculate and recalculate a national 
business case. 
Three rounds of business cases based on the initiatives within the action plan were 
conducted. First, the ex-ante expectations of expense-reductions were formulated in 
the action plan and were presented for each of the initiatives based on the business 
cases used to seek funding (33). Second, in the spring of 2015, an initial national 
business case was published (132) based on preliminary unadjusted results from 
KIH and TeleCare North for all included COPD patients. Third, in the spring of 
2017, the final business case is expected to be published based on the heterogeneity 
analysis of COPD severity in TeleCare North.  
Relying almost entirely on business cases for decision-making became the subject 
for a panel debate in the media from April to May 2016 following the decision to 
implement telehealthcare in Denmark. The debate was initiated with a critical recap 
(150) of the economic potential described by business cases in the action plan (33) 
and the initial national business case that were based on preliminary results from 
both KIH and TeleCare North retrieved in the spring of 2015 (i.e. the first and 
second rounds of business cases) (132). This recap demonstrated that the national 
cost-saving expectations was gone from 1,600 full-time equivalents (FTEs) to a 
negative profitability for all the KIH projects (DKK 0.1 mill.) and from cost-
savings around 700 FTEs to a negative profitability (DKK 5 mill.) for all 1,225 
patients in TeleCare North. This lead the author to conclude that particularly ex ante 
business cases were manifestations of “fever fantasies” (150) and that other 
evaluation approaches, such as HTAs, should be applied in the future instead (159).  
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Indeed, the evidence mentioned in the formulation of the “national action plan for 
dissemination of telemedicine” (33) were based on a questionable evidence 
synthesis methodology that lead to high ex ante expectations. In addition to the 
business cases used to seek funding (where a “positive” business case was a 
selection criteria…), the following argument were used illustrating this point:  
“…there are great expectations for the economic potential of 
telehealthcare solutions - partly on the basis of small pilot projects in 
Denmark, and partly on the basis of major implementation projects 
abroad, e.g. Scotland and the UK. The British Ministry of Health 
have in December 2011 announced the preliminary results of a large-
scale demonstration project with the following conclusions: The early 
indications show that if used correctly, telehealth can deliver a 15 
percent reduction in emergency visits, a 20 percent reduction in 
admissions, a 14 percent reduction in bed days and an 8 percent 
reduction in tariff costs. More strikingly they also demonstrate a 45 
percent reduction in mortality rates" (33, p6) (translated from 
Danish). 
It turned out that the expected outcomes of telehealthcare referred from the press 
release were based on 6,191 patients from the Whole System Demonstrator Project 
(WSD) that were never published scientifically. Critics within the UK and abroad 
did also heavily criticize the British Department of Health for the press release 
saying that these results were “sensationalist and cherry-picked” from unpublished 
data (171). It is also unclear which “small pilot projects in Denmark” that are 
referred to, but most notable studies had been pilot efficacy trials completed in 
North Denmark Region (22,172), the Capital Region of Denmark (23) and in the 
Region of Southern Denmark (24). The North Denmark Region study included a 
trial-based economic evaluation and concluded that telehealthcare was cost-
effective after 6 months for the included 111 patients (60 in intervention group) 
with severe and very severe COPD (172). The Capital Region study did not include 
an economic evaluation, but concluded that no statistically significant differences 
were found in health-related quality of life at 3 months (23). The Region of 
Southern Denmark study found no statistically significant difference in mortality or 
readmissions at either 4, 8, 12 and 26 weeks for 266 patients with severe COPD 
(132 in telehealthcare group) (24).  
Both Danish Regions and the Danish Agency for Digitalization has defended the 
use of business cases by stating that they are the “best solution” (149) and “the 
only” general standard for prioritization within and between sectors (142). But they 
also recognize that business cases must include “qualitative” evidence as well and 
be continually updated (142). Indeed, the national business cases were updated with 
input from the initiatives in the action plan. Answering only for the TeleCare North 
trial; the changing cost-conclusion reflect a move from an efficacy trial (the 
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efficacy trial in North Denmark Region that was the foundation for the business 
cases calculated here), to an effectiveness trial, where outcomes can be smaller than 
under ideal circumstances (an efficacy vs. effectiveness issue). It also reflect that 
the efficacy trial in North Denmark Region only included patients with severe and 
very severe COPD, where patients with severe COPD later turned out to be the only 
severity-group that were likely to lead to cost-savings in TeleCare North (a 
“selection bias” issue) (130). But health economists would not agree that business 
cases are the best, nor the only, option for prioritization within and between sectors, 
as described in the theory-chapter (82). Making such strong claims must be because 
full economic evaluation is unfamiliar or undesired by decision-makers. 
That there is a lack of recognized requirements for the quality of documentation of 
evidence in business cases is a challenge, which was also pointed out (143):  
“…it is important to note that decisions should not be based on an IT 
manager, two project nurses or fifteen specially selected patients that 
find the effect of telehealthcare good, but that there exist a high level 
of evidence" (143) (translated from Danish). 
The KIH business case results were published first in August 2015 (108). There 
were differences in the profitability of the five included initiatives, but there were a 
negative profitability overall across initiatives. The results from the COPD initiative 
targeted patients with severe COPD demonstrate a 21% negative profitability 
primarily due to no difference in the number of and duration of hospital admissions 
and the intervention costs (108). But the KIH evaluation was subject to harsh 
criticism by health economists for its business case design and applied methods, 
e.g. for not including all relevant intervention costs, for including only labor saving 
costs, for being an efficacy trials with questionable scalability of the conclusions 
and for including expert opinions instead of actual data on resource use in many 
cases (147,158) leading one author to state:  
“If it was one of my economics students who had handed in the KIH 
report, I would have flunked this student” (158) (translated from 
Danish). 
In many ways the business case format deviates from the design of standard health 
economic evaluation and can in some ways probably be better described as what 
health economists calls budget impact analyses that can be used to complement 
health economic evaluation (173). In addition to the evaluation design, the main 
difference can be found in objectives; while health economic evaluation evaluates 
costs and health outcomes for their technical efficiency for resource allocation 
decisions, budget impact analyses addresses cash flows related to development and 
implementation in order to assess affordability for the involved stakeholders (173). 
This could explain why the methodological approach was seen as “the only” and 
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“best” solution, if stakeholders are used to evaluations based on affordability. But 
then evaluation skips a step, where affordability becomes a more important criterion 
for resource allocation than efficiency. And the use of business cases can only be an 
approximation to budget impact analyses, since business cases are not based on a 
logic of evidence hierarchies (budget impact analyses are) and the epidemiology 
and/or etiology of the disease under investigation are seldom used in business cases 
(budget impact analyses do). In contrast to health science, where an “evidence 
hierarchy” is one of the foundations for assessing study quality and designing 
studies with a high validity, there is no stringent methodology for designing 
business cases or for choosing underlying studies here. If business cases apply 
studies at the lower levels in the evidence hierarchy, there is a risk that they will 
become misleading in interpreting a causal link between the telehealthcare 
technology and observed outcomes. In this regard, it is interesting that the action 
plan initially suggested an HTA approach to evaluation (33), which was not 
conducted in practice. The advantage of an HTA approach would have been that the 
methodology applied here is based more on a health science tradition of grading 
evidence and reflecting the investigated disease.   
5.3. STUDIES USED  
The economic evaluation of TeleCare North was presented to the public three 
months after KIH in November 2015. The main conclusion for all 1,225 patients 
(article 4) was presented along with a heterogeneity analysis of especially 
differences in cost-effectiveness across patients with different COPD severities 
(article 5). The heterogeneity analysis in particular comes to the opposite 
conclusion than in KIH by concluding that the probability of cost-effectiveness is 
higher for patients with severe COPD.  
That the economic evaluation in TeleCare North was allowed to deviate from the 
business case format became essential to the decision and it has been used actively 
by highlighting that it was a health economic evaluation from TeleCare North that 
were used as input to the national business case (142). The unpublished and not 
peer reviewed results from the economic evaluation of the TeleCare North trial 
therefore became the main evidence used in the decision to implement 
telehealthcare in Denmark (138). Although, the KIH project is mentioned by the 
Danish Agency for Digitalization, the emphasis is officially made on describing the 
experiences from TeleCare North and in contrast to TeleCare North, no links are 
provided to KIH on the web-page informing about the dissemination of 
telehealthcare in Denmark (138).   
“Good experience from two large scale telehealthcare projects 
Telecare North and KIH, has paved the way for the political 
agreement […]. Lessons from especially Telecare North shows that 
telehealthcare increases the quality of life for people with COPD, 
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because the citizen experience increased security, freedom and being 
able to act for themselves during exacerbations […]. Read more 
about the experience of Telecare North" (translated from Danish) 
(138). 
The same critical voices that questioned the validity of the KIH study have 
criticized this single-study strategy (144): 
“Based on, at best, a single analysis documenting cost savings  - 
other studies are "forgotten" - is an economic agreement for 2016 
between the Danish Government, Danish Regions and Local 
Government Denmark agreed that involves nationwide dissemination 
of telemedicine for COPD patients by the end of 2019” (translated 
from Danish) (144). 
There are no publicly available documents and information on national decision-
makers motives for choosing to focus on the TeleCare North evaluation, so there is 
no way of knowing whether it was because of the criticism raised of the KIH 
evaluation or for some other reason. But there were other options, than deciding to 
disseminate telehealthcare to COPD patients based on a single study.  
One option was to apply evidence generated internationally that used a comparable 
design (i.e. a cost-utility analysis) and some studies did exist, primarily from the 
UK: The WSD in England had been published as a series of publications from 2012 
to 2015. The overall results are not specific to COPD (they include patients with 
diabetes and heart failure as well), but still interesting, since they provide the first 
large-scale evidence on the effects of telehealthcare in the world and as such are 
hard to ignore. The cost-effectiveness study by Henderson and colleagues 
concluded that the telehealthcare solution was unlikely to be cost-effective after 12 
months (ICER=£92,000; probability of cost-effectiveness=11% at £30,000) (125) 
and previous results had already demonstrated a reduction in mortality and overall 
admission proportion and bed days, while differences in other hospital use (elective 
admissions, outpatient visits, emergency department visits) were non-significant 
(125). In addition, there were no improvement in health-related quality of life or 
any of the psychological outcome measured (126). Rixon and colleagues published 
patient-related outcomes for the COPD subgroup within the WSD in 2015 (123) 
and concluded that the 447 participants showed that telehealthcare had a “minimal 
effect” on health-related quality of life and psychological distress and only 
emotional functioning and mastery were significantly higher with telehealthcare  
(123). In Scotland, the Telescot program was also focusing on telehealthcare for 
various patients with chronic diseases (174). A 12 months clinical trial from 
Telescot testing the effectiveness of a telemonitoring solution specifically to COPD 
patients concluded in 2013 that telehealthcare was not effective in improving 
health-related quality of life, postponing hospital admissions or reducing the 
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number and duration of readmissions (128). This was later followed by the results 
from the economic evaluation alongside the trial, which revealed that the 
telemonitoring intervention gave rise to higher costs, which meant that the 
intervention was unlikely to be cost-effective (ICER=£137,277 per QALY; 
probability of cost-effectiveness=15% at £30,000) (127). 
These international results were acknowledged by decision-makers and are 
described directly in an overview of experiences that was reported as part of the 
implementation of the action plan (25, pp39-41). But international studies are 
excluded from the synthesis in the initial national business case conducted by PA 
Consulting group (132, p1).  
A second option would simply have been to postpone a decision until further 
(Danish) evidence existed. Both options could have been founded on a decision-
model with a value of information analysis as described in the theory-chapter. 
5.4. HIGHLIGHTED RESULTS 
The economic evaluation of TeleCare North was designed as a full economic 
evaluation. In this regard, it is interesting that none of the identified sources, other 
than the scientific studies, actively use the ICER (additional cost per QALY gained) 
that directly relates costs with an outcome. Instead results from TeleCare North are 
transformed into results used in partial evaluations with much emphasis on cost-
savings in both the national business cases and in the communication about the 
results.  
The results from the subgroup of patients with severe COPD in the economic 
evaluation quickly came into focus with the cost-savings that were likely here.  
“[Heading: Economic gains depend on the target group]. TeleCare 
North has shown that the economic benefits of telemedicine are 
greatest for people with severe COPD. TeleCare North estimates that 
for this group annual savings are DKK7,000 annually per patient to 
the municipalities and regions. This cost-saving is mainly due to 
fewer hospitalizations. If telemedicine is offered to all patients with 
COPD regardless of COPD severity it is associated with additional 
costs of approximately DKK5,400 per person per year. The reason is 
that telemedicine cannot reduce the number of admissions to the 
same extent for the entire target group as with citizens with severe 
COPD" (133) (translated from Danish). 
In health research, it can be difficult for analyses that investigates subgroup 
effectiveness to be published, because these results are explanatory, meant to 
inform clinical practice and there is a risk that effects are found by chance (175). 
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However, it is entirely appropriate to conduct subgroup or heterogeneity analysis in 
cost-effectiveness research used for decision-making, because these are concerned 
with whether or not to fund certain courses of action, not treatment (176,177). 
However, there are certain procedures and ways to report findings from 
heterogeneity analysis that must be met (176,177). In health economic evaluation 
this is done by pre-specifying potential subgroups prior to analysis and these should 
be likely to be operationalized in routine practice and give clinical or economic 
meaning (176,177). But contrary to health research traditions, reporting results from 
subgroup analyses are not based on differences in treatment-by-covariate effects 
being statistically significant (176,177). Rather, the uncertainty surrounding the 
cost-effectiveness estimate in subgroups are quantified, mostly by a technique 
called “probabilistic sensitivity analysis” (176,177).  
In the national debate following the dissemination of telehealthcare, some argued 
that the focus was too much on the subgroup of severe COPD (144). I have 
responded that the reporting of subgroup results from the economic evaluation of 
TeleCare North in the decision-context has been mostly fair and balanced (153). A 
focus on the subgroup of severe COPD could also reflect a desire from decision-
makers to communicate why this decision was made and that the overall results 
were always presented along with the subgroup results (153).  
But some of the results from the economic evaluation of TeleCare North were used 
without some of the reservations or precision that must be made. For example, it is 
stated that there is an effect on quality adjusted life-years both in the overall trial 
results and in selected subgroups: 
“The health economic research shows that telemedicine has an effect 
measured in quality-adjusted year of life for the vast majority of 
patients. The effect is very similar to the results from the Whole 
System Demonstrator project in England. The research also shows 
that telemedicine for patients with COPD should be targeted […]. 
When telemedicine is targeted to patients who have severe COPD, 
GOLD 3, it is possible to achieve an effect in terms of quality-
adjusted life years while saving costs. The cost-savings are around 
DKK7,000 per citizen" (108) (translated from Danish). 
It is true insofar that health economists are interested in the absolute differences in 
outcomes and costs in the calculation of an ICER (178). But if health outcomes are 
reported separately from costs, it is still necessary to focus on statistical 
significance in order to inform clinical practice (178). Instead, the results from 
probabilistic sensitivity analyses should have been much more in focus, but are only 
mentioned by researchers. More precision in communicating the results could be 
warranted, but it is a complex message to understand and communicate when no 
health economic tradition is routinely applied in decision-making. 
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Some have critiqued that health or patient-related outcomes were missing from the 
national decision (140,141,146). This is partly because few effectiveness studies 
had been conducted at the time of the decision (e.g. mortality or physiological 
indicators were secondary outcomes in the trial and not analyzed at the time of the 
decision). But the effectiveness study from article 3, reporting the results of the 
main trial outcome (no statistical significant difference in health-related quality of 
life measured by SF-36 on all 1,225 patients or any subgroup) were presented 
alongside the economic evaluation, but this result is not highlighted anywhere. 
Patient-related outcomes that were published first while the clinical trial was being 
implemented, such as initial positive user experiences with the Telekits and the 
increased sense of security and control it lead to for them, were used to support the 
decision made, e.g. in the initial national business case (132) and in the 
communication by the Danish Agency for Digitalization (133). However, these 
results could also have been used with more precision: A representative from 
Danish Regions summarize the results from TeleCare North in the following 
symptomatic way (156): 
“[Heading: Clear benefits]. The benefits of the upcoming nationwide 
dissemination of telemedicine are clear. In the middle of November, 
the parties behind one of Europe's large-scale projects in 
telemedicine, Telecare North, published the results of nearly four 
years of investigation by almost 1,400 COPD patients from North 
Jutland. The conclusions were:  
• 6 in 10 people feel that they can better control their own illness with 
telemedicine. 
• 7 out of 10 feel safer in everyday life with telemedicine. 
• 9 out of 10 find the telemedical equipment user-friendly” (156). 
But these data were published in a conference proceedings journal and only based 
on 60 patients from the intervention group before the trial was completed (179) and 
the representativeness of these patients to the decision made are uncertain (e.g. all 
60 patients did not have severe COPD).  
5.5. HIGHLIGHTED DECISION-UNCERTAINTIES 
In addition to mentioning that the organization of telehealthcare monitoring may be 
different in each region (108), when telehealthcare is eventually disseminated in 
Denmark and the potential for targeting the peripherals in the Telekits in the 
national business case (132), little is communicated to the public about decision-
uncertainty on the national arena. One reason was that the scientific papers from 
TeleCare North, with the reservations described herein, were in peer review and 
could not be disclosed publically.  
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But in the national debate of the strengths and weaknesses of business cases, a 
representative from Danish Regions revealed that there was decision-uncertainty, 
but also that it is important to take risks (149): 
“It takes courage to drive public sector development. It would be 
easy to simply looking at everything that is going well and not take 
any further action. We have in Danish Regions chosen a different 
strategy which implies that we sometimes have to take a chance and 
take risks in order to grow and to create better solutions” (149). 
The Danish Agency for Digitalization do make a reference to decision-uncertainty 
(134) by linking to a report published by North Denmark Region in November 2015 
that contains their experience with the implementation of the TeleCare North 
initiative (108). In it, a set of major circumstances are highlighted that they feel 
could potentially have affected the outcomes of the TeleCare North trial, which are 
not accounted for in the sensitivity analyses made in the economic evaluation.  
First, the initiation of TeleCare North coincided with a national labor dispute 
between the Danish Medical Association and Danish Regions in 2013 (108). 
Although, there was positive support for TeleCare North by the Danish Medical 
Association and most GPs in North Denmark Region, some GPs were assessed to 
influence the initiative negatively by affecting both cooperation and dialogue. This 
made it challenging for municipalities to have “a standardized and close dialogue 
with general practice for all their citizens” (108).  
Second, TeleCare North used existing national solutions and contributed to the 
establishment of a new national IT-infrastructure where IT-solutions were missing 
(108). A central national IT-solution to be developed was a dataset 
(“Kronikerdatasættet”, no English translation) that should allow for cross-sectorial 
data-sharing of home monitoring data between GPs, municipalities and hospitals 
and integrated into existing local IT-systems. The work with this dataset was 
eventually disbanded. Instead, a web-based portal solution was made for TeleCare 
North (“OpenTele”) to allow for data-sharing between municipalities and hospitals 
and an existing portal (“www.sundhed.dk”) was used by GPs (108). This meant that 
the cross-sectorial coordination could probably have been even better throughout 
the trial period. The national decision therefore also acknowledged that a 
prerequisite for implementation is an increased maturation of the IT-infrastructure 
to further support telehealthcare monitoring (113). 
Third, introducing telehealthcare required new skills to be learned especially for 
nurses, since they were given the task of training and monitoring patients (108). 
This was a new task involving training in order to be able to read and evaluate the 
conducted measurements, to recognize any relevant patterns or change in the 
development of vital values in patients and to be able to act proactively (108). 
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Combined with challenges in making the hardware and software configuration 
running smoothly, this could have led to a “significant overuse” of resources in the 
beginning of the trial (108):  
“Hospitals, municipalities and general practice have entered into the 
project without any experience. This meant that an organizational 
maturation occurred while data was collected from the control and 
the inclusion group for the evaluation […]. Our assessment is that we 
were far into the research efforts before well-established routines and 
skills associated with the telehealthcare effort was established” (108, 
p40). 
A comprehensive search for heterogeneity and the effects of changed assumptions 
was also conducted post hoc in order to come closer to demonstrating why the 
telehealthcare solution was not more cost-effective than demonstrated. Much of this 
work is unpublished, but central points have been included in the sensitivity 
analyses in the main cost-effectiveness analysis in article 4 and the heterogeneity 
analysis in article 5. The overall results were relatively robust to changed 
assumptions, but heterogeneity analyses demonstrated higher probabilities of cost-
effectiveness for “system-variables”, than for any health- or socio-demographic 
characteristics, i.e. there were variations from 0% to 100% in the probability of 
cost-effectiveness across municipalities and the probability of cost-effectiveness 
was much higher for patients having existing resource use in the municipalities at 
evaluation outset than patients who did not (89% vs. 18%) (130). Of course 
targeting patients based on contacts with healthcare providers would be considered 
unethical, but it does indicate that “implementation” could be important for 
achieving cost-effectiveness, which is also argued in article 5 (130).  
This point was also made by fellow qualitative researchers from TeleCare North in 
the national debate (151,152). Based on the qualitative research conducted in 
TeleCare North, it was e.g. argued that the TeleCare North initiative is about 
organizational development and change requiring constructive cooperation on all 
organizational levels, conflict resolution techniques, local adaption and continuous 
attention and adjustments that might not even be fully in place to this day:  
“To implement a cross-sectorial telehealthcare solution is not 
something you do with a snap of the fingers. But if it can be done, the 
potential of telehealthcare can prove to be even greater than the 
TeleCare North evaluation has demonstrated, because the concept is 
still evolving” (151) 
That implementation is “crucial” to the effects of telehealthcare was also seen as 
implicating that quantitative evaluation methods needs to evolve in order to achieve 
a higher external validity (152). Trial-based evaluation methods developed in health 
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science and utilized in health economic evaluation does not sufficiently take 
implementation into account and should be complemented by “a conscious 
approach” to implementation (152).  
5.6. INTERPRETATION 
In Denmark, we have a more or less ad hoc national setup for assessing the effects 
of technologies such as telehealthcare. No single authority have the formal 
responsibility for ensuring that a systematic synthesis of evidence is conducted and 
to ensure that applied methods are suitable for the technology to be assessed. This is 
often seen as a disadvantage, since this implicates that the applied methodology and 
criteria for sound evaluations come to reflect the purview of the national 
institution(s), where the decision process is placed each time. Rather old Danish 
guidelines for economic evaluation of pharmaceuticals exist and the European 
Medicines Agency can be relied on approval of pharmaceuticals for the Danish 
market as well. But the only requirement for telehealthcare to be approved is in 
principle a “Conformité Européenne” (CE) marking on the equipment, which does 
not guarantee that the equipment actually leads to desired benefits. This will not 
change with the new “Medicinråd” established by Danish Regions in 2016 that in 
the near future only covers hospital medicine. 
On the other hand, the Danish “national action plan for dissemination of 
telemedicine” was an attempt at systematizing the testing and evaluation of 
telehealthcare in Denmark. A lot of good intentions were put into the development 
of the plan, e.g. a willingness to try a standardized evaluation mindset, attempting 
to coordinate the included initiatives, using large-scale cross-sectorial initiatives to 
test the implementability and cost-saving potential demonstrated in some efficacy-
trials (essentially a phased development mindset as with pharmaceuticals). But 
there were also significant lessons to be learned from this action plan and the 
evaluation approaches it contained as events unfolded, which are described below 
(relating to the themes “Methodological approach”, “Highlighted results” and 
“Highlighted decision-uncertainties”). 
In my opinion, the first lesson is that for telehealthcare there is no getting around 
making decisions that are based on underlying evaluations with a balanced outcome 
focus and randomization. These evaluations might be challenging, time consuming 
and expensive to apply alongside implementation, but we need these types of 
evaluations and it would also be difficult to engage healthcare professionals and 
researchers and convince them of the soundness in decisions, if studies with low 
internal validity and a single expense-outcome is used. The greatest risk of using 
business cases as a methodology for resource allocation, is that “qualitative effects” 
become secondary outcomes at best and that no criteria of what constitutes good 
evaluation designs is an inherent tradition here. I agree with the criticism that 
emerged from health economists in arguing that health economic evaluation should 
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be the foundation for resource allocation decisions, because these designs are 
designed for efficiency decisions and minimize the risk of bias and confounding, 
and because reporting of health economic evaluation are based on relatively 
scientifically well-defined good practices that are both transparent, standardized and 
stringent.  
However, we should remember that health economic evidence was useful for the 
decision and incremental costs was applied in the national decision-making process, 
albeit possibly by coincidence or foresight by stakeholders in North Denmark 
Region, and mostly translated into a budget impact form. The decision to 
implement telehealthcare in Denmark relied on a single-study strategy that was part 
of the evidence foundation for the national action plan (the TeleCare North trial). 
This can be viewed as a start, even though a single-study approach is not 
recommended for health care decision-making and TeleCare North was not a 
“reference case” trial-based economic evaluation either. Other options were 
available such as including other evidence (e.g. from KIH or international evidence 
generated from 2013-2015) or choosing to postpone a decision. In that way, more 
data for calculating the expected costs and/or benefits of telehealthcare could have 
been included in decision-making. But that could have been a challenging argument 
to sell to decision-makers given the effort and expense that were spent in the action 
plan. 
A second lesson is that telehealthcare interventions are difficult to implement and 
that effects of implementation can be hard to foresee, quantify and make visible in 
cost-effectiveness evaluation. Several factors could in theory have affected cost-
effectiveness outcomes positively and negatively in TeleCare North and some 
concrete factors were mentioned. This underlines that a health economic evaluation 
cannot be seen in isolation, without the circumstances it was conducted in and that 
implementation can have an impact on the evaluation result. With trial-based 
economic evaluations, we usually have no direct way of demonstrating if we have a 
telehealthcare solution that has released its full cost-effectiveness potential or if this 
potential has been hampered by a “not optimal” implementation or other contextual 
factors to a certain degree. 
Combining these two “lessons” creates a pressing issue. It would probably be too 
far-fetched to claim, that national decision-makers are ready for making decisions 
based on traditional health economic evaluations in the future. Politically or 
administratively, there might be an increased recognition of the strengths of health 
economic evaluation of telehealthcare in answering if telehealthcare works and for 
whom compared to other research designs, e.g. more initiatives are now tested in 
Denmark and North Denmark Region has received national funding for a new 
initiative, “TeleCare North 2” to chronic heart failure patients that includes a new 
trial-based economic evaluation to be used for national resource allocation 
decisions (137). If such an increased recognition of trial-based economic evaluation 
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has gained momentum, then we also need better trial-based economic evaluations 
that address challenges that are threatening both internal and external validity. As 
long as the usefulness of single cost-effectiveness studies could easily be called into 
question, it becomes less relevant to debate which approach for evidence syntheses 
should be chosen in resource allocation decisions. From both a scientific and 
decision-maker standpoint, there is a need for developing trial-based economic 
evaluation of telehealthcare by incorporating design elements that lead to higher 
decision-certainty. When decisions has to be made of whether or not to disseminate 
telehealthcare solutions from one region to the entire country, is it enough to answer 
questions such as “was telehealthcare cost-effective and for whom”, when there is 
an increased need to answer questions such as “how can the intervention be 
improved or adapted to be more cost-effective?” and “how much more cost-
effective can telehealthcare be expected to be?”.  
Failing to address these types of questions can result in “trench warfare” every time 
trial-based economic evaluations of telehealthcare are published. For example, in 
interpreting the results from recent trial-based economic evaluations, one position 
could be that these recent studies of telehealthcare are larger, have broader cost 
perspectives and are more pragmatic, so telehealthcare is not cost-effective and 
earlier studies suggesting the opposite conclusion are questionable laboratory 
experiments with poorly designed cost-studies. The opposite position would be that 
telehealthcare is cost-effective and failure to demonstrate this in recent studies is 
because newer studies have a lower internal validity and are not strict replications 
of older studies, so something in the intervention or evaluation have gone “wrong”. 
If decisions to implement telehealthcare or not depends on a dominant coalition of 
stakeholders belonging to one or the other of these positions, we have really not 
demonstrated genuine interest in bringing research and better decision-making 
forward. The usefulness of trial-based economic evaluation in healthcare resource 
allocation would therefore be open to easy criticism and we fail to utilize the 
momentum that could have been generated or we risk implementing a system of 
“opinion-based evidence” - which is a contradiction in terms of course. In this 
regard, that we do not have a systematic approach for including economic evidence 
in healthcare resource allocation in Denmark, could actually also be seen as an 
opportunity to investigate what health economic evaluators can do differently or 
better in order to achieve an even broader foundation for decision-making. 
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CHAPTER 6. REFLECTIONS ON 
HEALTH ECONOMIC EVALUATION OF 
COMPLEX TELEHEALTHCARE 
INTERVENTIONS
This chapter is based on reflections initiated by decision-makers and other 
researchers across the country that have asked me each time I was invited as 
speaker on conferences or meetings throughout 2016: “Why was TeleCare North 
not more effective and cost-effective?” and “Could you point to what could be done 
differently in future implementation or evaluation of telehealthcare?”. Based on the 
TeleCare North evaluation, no firm answers to these sorts of questions can be made, 
but they sparked the initiation of a search for theories, experiences and evaluation 
approaches that could inform future trial-based economic evaluations. The topics 
covered in this chapter are grounded in health economic evaluation theory, 
experiences with the evaluation design of TeleCare North and its implementation as 
well as themes from the national debate of evidence. These topics are combined 
with different evaluation paradigms and theoretical approaches to evaluation that 
could be relevant for trial-based economic evaluation of telehealthcare. In this 
respect, this chapter wants to create a discussion of how to develop trial-based 
economic evaluation of telehealthcare further by inductively attempting to add 
theory to existing trial-based economic evaluation.  
6.1. ACKNOWLEDGED CHALLENGES IN THE EXISTING COST-
EFFECTIVENESS EVALUATION APPROACH OF 
TELEHEALTHCARE 
In general, a strong case has been argued for conducting trial-based economic 
evaluations of medical devices in general and by implication also telehealthcare 
(180–182). These technologies are also incorporated into the program by NICE 
(183,184). Conducting trial-based economic evaluations is considered a strength 
since it borrows the internal validity of randomization from the clinical trial. 
Randomization should ensure that patients in the alternatives are comparable in 
every way except the treatment under consideration, which leaves only the different 
treatments as explanations for observed differences in outcomes (96). In other 
words, if research questions explicitly involve cost-effectiveness objectives (i.e. 
determining whether or not there is an extra effect or costs of an intervention and 
the magnitude of these extra effects), then experimental evaluation must be at the 
top of the “evidence hierarchy” (90).  
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But, it is increasingly recognized within health economic research that medical 
devices such as telehealthcare are different than the pharmaceuticals that economic 
evaluation were developed for assessing and that this poses unique conceptual and 
practical challenges that are difficult to handle in existing trial-based economic 
evaluation (181,182,185–188). These challenges are primarily seen to constitute 
threats to internal validity: First, constraints in study design primarily related to 
problems with blinding telehealthcare initiatives in the underlying trial have several 
implications. Involving both a device, training and monitoring, it cannot be avoided 
that it becomes visible who receives treatment and who does not in telehealthcare 
trials (182,185,186). This implicates that patients or healthcare personnel risk 
affecting trial outcomes, e.g. by having or giving different expectations to treatment 
alternatives, by affecting trial drop-out or by implementing heterogeneous 
administration of interventions (100). A real risk of contaminating treatment 
alternatives are also present, since intervention patients or healthcare professionals 
can inadvertently use intervention training (e.g. disease specific training) on control 
patients (165). Patients may also refuse to enter the clinical trial if they are afraid of 
using or are unfamiliar with the device and disappointed patients can choose to drop 
out of the trial after being randomized to control treatment (165). Second, there are 
many more explanatory factors for telehealthcare cost-effectiveness than for 
pharmaceuticals (185,188); telehealthcare cost-effectiveness can e.g. vary with the 
user friendliness of the device and peripherals, many different characteristics of 
patients, the skills of health professionals and the organizational setting (188). 
Third, learning curve effects are plausible, since baseline skill and experience of 
patients and health professionals in using telehealthcare will change over time. This 
means that cause-and-effect assessment entails comparing familiarity with one 
alternative compared to unfamiliarity with the intervention, adding a dynamic 
element to cost-effectiveness evaluation (181,182,185,186) Fourth, wider 
organizational implications of adopting telehealthcare is likely (181,182,186), e.g. 
implementing telehealthcare often entails reorganization of services and work 
flows. 
One way to meet some of the challenges with internal validity of trial-based 
economic evaluation of telehealthcare (primarily the first and second challenges 
from above) have been to focus on even more sophisticated designs, more 
complicated statistical analyses and elaborate data collection, such as the CRT 
design (189,190). This could minimize the risk of contamination and allow for 
inclusion of organizational-level covariates. But designing and implementing CRTs 
has a “price”: Firstly, CRTs are less statistically efficient than RCTs (165). 
Depending on how many patients that are in each cluster and how correlated 
outcomes are within these clusters, the required sample size necessary for achieving 
sufficient statistical confidence in the results can be significantly larger than for 
RCTs. There is generally a need for larger studies in telehealthcare research, but 
conducting CRTs reinforce this need. And large studies are expensive and time 
consuming. Secondly, selection bias is a greater concern for CRTs and can be 
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difficult to avoid in practice (165). Because CRTs applies a different randomization 
unit (i.e. the general practitioners in WSD or municipalities in TeleCare North), 
preparation of delivery organizations become challenging. In order to conceal 
treatment allocation, delivery organizations (and patients) must be recruited before 
randomization. But why should delivery organizations e.g. send healthcare 
professionals to courses in disease-specific training or in using the telehealthcare 
equipment, if they end up being allocated to control treatment? Preparing delivery 
organizations after randomization could in theory be done. But in large-scale trials 
this would usually result in a much delayed implementation of telehealthcare at the 
patients’ homes leaving a much shorter period for the intervention to have an effect 
in the trial period. And this strategy can also be unethical if it leads to study drop-
outs (increasingly ill patients will likely have a reduced cognitive or emotional 
energy over time and risk dying!). Thirdly, compared to randomizing individuals, 
imbalances between treatment alternatives have a higher chance of occurring in 
CRTs, particularly if the numbers of clusters are small (165). Methods for avoiding 
and adjusting these imbalances should therefore be used to a larger extent (e.g. 
using cluster-covariates in addition to patient covariates or by matching clusters). 
However, methods for trial-based economic evaluation are not as well-developed as 
cost-effectiveness methods alongside RCTs. Although, some authors have pointed 
to potential methods for analyzing cost-effectiveness data in CRTs (167,191), it is 
still a field very much in development. Depending on the concrete design of the 
CRT (the number and balancing of clusters and number of participants within 
clusters) as well as the “behavior” of the data, there are several statistical methods 
that can be applied. None are optimal and all of them would probably not yield 
different cost-effectiveness conclusions, but certainly different sizes of incremental 
cost and incremental effects. Fifthly, variations in local treatment by delivery 
organizations within and across clusters, e.g. in how training was actually 
conducted, who and how measurements were conducted or monitored, are much 
more difficult in CRTs, because activities are dispersed over different locations. A 
way to handle this is to demand that delivery organizations adhere to strict 
treatment protocols, but this may be hard to accept by them and adherence in large-
scale evaluations is very difficult to control as a researcher.  
The third challenge (learning curves) also implicates that patients and delivery 
organizations undergo a “shakedown phase” after implementation, i.e. because it 
takes time to learn new skills and to adapt new daily routines and work flows (192). 
Figure 3 illustrates (probably an exaggerated point) that evaluating cost-
effectiveness in this time period may not reflect the likely cost-effectiveness that 
could be expected when the telehealthcare technology finds its steady-state 
operation over time for patients, healthcare professionals and the involved 
organizations.  
HEALTH ECONOMIC EVALUATION OF TELEHEALTHCARE 
78
Figure 3: Two different learning curves illustrating that incurred costs and outcomes can be a function 
of time. Source: Own contribution 
 
Practical solutions include allowing patients and healthcare professionals to gain 
familiarity with the telehealthcare intervention before beginning the evaluation. But 
identification of a steady-state operation can be difficult (e.g. if curves do not 
flatten as they do in Figure 3) and it would lead to a shorter trial-duration. Instead, 
some learning curve effects was incorporated in TeleCare North post hoc by 
analyzing the impact on cost-effectiveness of reducing the average time spent per 
patient on monitoring physical measurements to reflect the monitoring time used in 
the end of the trial period (129). Another solution is to use expert users, but this 
would come into conflict with the “effectiveness” objective of the economic 
evaluation, where the interest is on the likely effects as close to real practice as 
possible. To address organizational implications (the fourth challenge), an 
unpublished sensitivity analysis focused on the failure to reorganize workflows 
surrounding outpatient visits by eliminating certain visits from the cost-
effectiveness calculation and analyzing the impact (some patients were requested to 
show up for an outpatient visit where physical measurements were taken instead of 
using the measurements conducted at home, since hospitals in some cases forgot or 
could not see that patients were included in the TeleCare North trial).  
So, some learning curve effects and wider organizational implications can be 
handled by traditional sensitivity analyses in trial-based economic evaluation, 
especially post hoc, but in general they are a challenge in experimental evaluation 
(i.e. it can be difficult to identify a priori where learning curves and organizational 
implications would take effect before evaluation). Should experience-based 
requests for modifications of technology or work flows after evaluation initiation 
arise (e.g. if it is discovered that more optimal work flows or technology features 
would lead to higher effectiveness or lower costs), an adaptation of the intervention 
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in the evaluation period is generally rejected in clinical trials, since this could 
introduce confounding. This was also an issue in TeleCare North, where 
modifications were requested but halted by evaluators in order to maintain internal 
validity in the trial. An “easy” theoretical solution to this challenge is to conduct 
faster evaluations, but a requirement for economic evaluation is that the duration of 
the study should be as long as possible in order to capture all relevant benefits and 
costs (82). This duration is ideally sometimes several years, which means that the 
results from a cost-effectiveness analysis of telehealthcare risk being obsolete by 
the time of publication.  
In summary, conducting “traditional” trial-based economic evaluation of 
telehealthcare can therefore be a huge and challenging undertaking that requires 
significant time, funding and data. If sophisticated designs and analyses are applied 
and if practical dilemmas are addressed to the advantage of evaluation, some of the 
issues surrounding internal validity are solved. But the scale and complexity of the 
evaluation approach makes it a project that cannot realistically be conducted 
routinely. And it would still be a task permeated with analytical dilemmas 
especially related to a priori identification of learning curve effects and wider 
organizational implications of implementing telehealthcare. This has lead a review 
from 2015 to conclude that the implications of the unique characteristics of medical 
devices are “either not addressed or insufficiently addressed” in economic 
evaluation (186). However, few concrete solutions are provided and if they do, they 
usually take the form of analytical adaptations to account for problems with internal 
validity (181,182,185–188).  
6.2. REALISTIC EVALUATION AS AN ALTERNATIVE 
EVALUATION CONCEPT 
Instead of focusing on internal validity in answering “what worked and for 
whom?”, a few health economists have argued that trial-based economic evaluation 
should instead focus more on addressing implications of the clinical logic 
underlying health economics in order to move health economic evaluation forward 
(193–195). In order to achieve higher explanatory power and usefulness for 
decision-makers, it is necessary to focus more on external validity to account for the 
context in which interventions are embedded and the agency of participants in 
producing those outcomes (193–195). Health economic evaluations are conducted 
as “largely a-theoretical exercises in measuring or estimating the inputs (resources 
and costs) and outcomes” as a health economist recently put it (196, p328).  
Theory of agency and context are core evaluation elements found in “realistic 
evaluation” (197). Originating from a completely different philosophy of science 
paradigm, critical realism, the realistic evaluation tradition is one of the harshest 
explicit critics of experimental evaluation. Originally termed by Pawson and Tilley 
in 1997, realistic evaluation completely discards experimental evaluation as a tool 
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for evaluation in the beginning of their book (chapter 2 “out with the old”), since 
experimental evaluation does not provide any real lessons by only answering if an 
intervention worked or not and sometimes for whom (197).  
It is argued that experimental evaluation has misunderstood scientific methodology 
by assuming that knowledge can be accumulated based on theoretically uninformed 
observations of outcome differences and descriptions of interventions (197). 
Experimental evaluation is said not to understand what really happens in the 
“change engine” of interventions, meaning that this design cannot explain why and 
under which circumstances benefits are (un)likely to occur (197). Much attention in 
experimental evaluation has been paid on concrete intervention activities and too 
little on change mechanisms and how they interact with each other and the context 
in which they must operate. Mechanisms are hidden and unobservable, but central 
underlying causal processes leading to outcomes that are triggered by activities in 
interventions and these mechanisms are highly sensitive of contexts (198,199). By 
only analyzing empirically how intervention activities lead to outcomes, critical 
realists would state that experimental evaluation relies on statistical association and 
not a theoretical foundation of causation (200). Bonell and colleagues highlight the 
implications of this lack of theoretical approach in the following way: 
“There is concern that RCTs designed primarily to identify whether 
or not a specific intervention is effective have focused too much on 
the internal validity of the trial, addressing the question of efficacy 
rather than broader questions of reach, effectiveness, adoption, 
implementation and maintenance. This has led to an evidence base 
that is dominated by high quality RCTs of poorly theorized 
interventions, with effects that are poorly understood and unlikely to 
be universally replicated in translation studies or real world 
implementation” (200, p2300). 
Using an (in)famous analogy from Pawson and Tilley (197) to further illustrate the 
point of missing causation theories, imagine firing a gun with help of gunpowder. 
Gunpowder consists of several ingredients and if one or more is missing or if the 
ingredients are mixed using a wrong recipe, then the gun will not fire. Furthermore, 
if you forget to pull the trigger, forget to put a bullet in the cartridge or if the 
gunpowder is wet, then although the recipe for gunpowder was correct, the gun still 
will not fire or fire blanks. So, the firing of a gun (outcome) is not depending on an 
“active ingredient”, but rather on the composition and interaction of ingredients 
(mechanisms), and the circumstances under which these ingredients must operate 
(context).   
In order to explain outcomes, realistic evaluators would therefore focus on 
identifying change mechanisms operating within interventions instead of focusing 
on the concrete activities applied and seek to explain or understand how these 
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mechanisms are influenced by factors in the historical-, social-,  institutional- or 
policy context in which the intervention is embedded. Indeed, some critical realists 
would even argue that “context is everything” when trying to explain outcomes 
(201). To explain cost-effectiveness of telehealthcare, it is therefore necessary to 
focus on which mechanisms that is responsible for leading to higher health-related 
quality of life, lower mortality and costs. It is also necessary to understand the 
contextual circumstances that (in)activate well-functioning mechanisms. The full 
cost-effectiveness potential of telehealthcare can only be expected if all 
mechanisms leading to reduced costs and better outcomes were activated and if the 
context in which these mechanisms operated all worked and functioned as “a 
coherent whole” (202).  
Having a control group is the reaction to the problem of explaining “context” in 
experimental evaluation, i.e. that it is possible to strip away other explanations that 
could contribute to explaining outcomes. But realistic evaluators would stress that 
contexts cannot be “bracketed out” in this way and controlled for: 
“Researchers who wish to understand how improvement works, and 
why and when it fails, will never succeed if they regard context as 
experimental noise and the control of context as a useful design 
principle” (201). 
Another criticism, is that experimental evaluation does not contain information that 
come close enough to the actual mechanisms of change and the contexts in which 
they operate in order to explain what works for whom under what circumstances 
(197). According to Van Belle and colleagues, the defining nature of mechanisms is 
that they are “a response to resources” offered (e.g. information, skills, materials, 
support) (198). In other words, what is relevant in order to understand outcomes is 
how participants react to intervention activities (i.e. changed their logic, values, 
attitudes, actions) (198).  
This means that explanations for outcomes such as cost-effectiveness are much 
more subtle than can be elicited from data that are usually included in experimental 
evaluation. Patients are not just defined by socio-demographics, disease severity or 
lifestyle, but have values, concerns and aspirations as well as cognitive and 
emotional ways of reasoning, which are not characteristics per se, but rather a 
mindset that could also depend on the actions of health professionals or the 
institutional context in which they all operate. Likewise, the outcomes of concrete 
intervention activities are not just dependent on characteristics such as if the 
activities were performed and their “dosage”, but concrete events and experiences 
that these activities lead to, such as how activities were introduced, performed and 
adapted. And health care systems are not just defined by characteristics e.g. their 
size, available funding or the number of health professionals employed, but also if 
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organizational cultures, incentive systems or management were supportive and 
enabling or not (202).  
The implication of a missing thorough theoretical understanding of mechanisms and 
associated contexts in experimental evaluation can only result in a body of 
empirical knowledge that is filled with mixed evidence (which is exactly the case 
with experimental telehealthcare research today):  
“The overall result is a multitude of trial teams […] testing various 
intervention packages of varying degrees of similarity and difference. 
Some of these interventions are reported as effective, some as 
ineffective and a few as harmful, and it is generally difficult if not 
impossible for either primary RCTs or systematic reviews to make 
firm conclusions about which intervention components are likely to 
have the most potential and which combinations of these will produce 
the greatest effects” (200, p2301) 
Critical realists will argue that “prediction” of outcomes is possible, but in order to 
understand what works for whom, why and under what circumstances, critical 
realists will seek to build and refine theory over time and increase confidence in 
predictions by accumulating lessons across different contexts (200). A process 
which they call continuously refining “context-mechanism-outcome (CMO) 
configurations” (197). What is initially needed is a literature-driven theory that 
incorporates contexts, mechanisms and outcomes. From this theory; several 
hypotheses could be made and analyzed empirically that explicitly relates CMOs 
together. These are not quantitative hypotheses to be tested; in fact the realistic 
evaluation framework would rely on methodological pluralism, i.e. a combination 
of qualitative and quantitative data to investigate empirically how mechanisms 
interact with contexts in order to produce outcomes. Finally, empirical 
investigations undergo a process of induction, where “findings” are not generalized 
to populations, but rather increasingly nuanced, specified and published in order to 
refine theories of causation that can be used as predictions across other 
interventions. This last step is perhaps the most distinguishing feature of realistic 
evaluation. 
To illustrate the evaluation approach applied in realistic evaluation and especially 
the process of refinement, consider an example of property marking. This example 
is mentioned by Pawson and Tilley (197, p89f), but I have added several nuances in 
order to concretize how mechanisms or context are continually refined (the refined 
part of the example is my own description). Property marking is chosen, because it 
is a very simple intervention with a single very specific outcome: Its purpose is to 
reduce the burglary rate in neighborhoods and in principle the intervention involves 
only two activities; marking certain goods in households and putting a sticker 
warning potential offenders on the front door or windows.  
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The empirical evidence for property marking has been mixed: Sometimes a reduced 
burglary rate is found, sometimes not (197). To come closer to an explanation of 
this mixed evidence, a theoretical basis is initially needed for understanding what 
mechanisms are affected by property marking that causes burglary rates to decline. 
Crime opportunity theory suggests that an offence is much more likely if an 
offender is motivated by perceiving that there are suitable targets (mechanism) and 
an absence of capable guardians (mechanism) (197). A property marking 
intervention might be hypothesized to reduce burglary rates by affecting how 
burglars perceive both targets and guardians: It could make participating 
households less attractive for burglars, because it signals that stolen goods from this 
household are more difficult for burglars to dispose of (deactivating mechanism: 
suitable targets). There could also be an increased potential for detection and 
prosecution of offenders by authorities if they are found in possession of stolen 
goods (activating mechanism: a capable guardian). These mechanism might be 
more likely to be (in)activated with property marking if the number of active 
offenders is small (context), since deterring those few offenders would have a 
drastic effect on burglary rates.  
Empirically investigating these mechanisms and contexts might result in a need for 
refinement when they are implemented in reality or implemented in a different 
setting (this is my own made-up illustration). The “capable guardian” mechanism 
might only be activated if burglars find a higher risk of getting caught and/or 
prosecuted persuasive enough (refined mechanism). Activating this mechanism can 
result from any number of events and vary in effectiveness from burglar to burglar. 
It might be more likely to be activated in a context where domestic burglaries are 
prioritized and receive publicity (some burglar perceptions might be affected by 
newspaper articles demonstrating a case where property marking did lead to 
apprehension and convictions, some burglars could be deterred by noticing that 
extra funding to burglar task forces have been prioritized etc.). These events are 
created by the conditions set by context and are in most cases not part of the 
intervention, but instead unpredictable, emerging factors affecting the activation of 
this particular property marking mechanism. If activated, burglary rates might 
decline, but only if it is aligned with other mechanisms and only due to reduced 
burglaries in households with property marking (same outcome). Similarly, the 
“suitable targets” mechanism might only be deactivated if offenders are convinced 
that all activities in property marking are actually being conducted, i.e. that they 
have not found examples where households are just putting stickers on the windows 
and not actually marking any goods (refined mechanism). However, the mechanism 
could be activated again over time if burglars adapt, e.g. if there are available cash 
that cannot be marked but targeted instead (refined mechanism). Finally, the 
number of potential offenders might be small, but if offenders are not local 
opportunists, but foreign professionals, then they are much more likely to have 
effective distribution networks for disposing goods outside the jurisdictive of the 
police and they are less likely to get caught (refined context). 
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The example is meant to illustrate that what distinguishes realistic evaluation from 
experimental evaluation is that it is not the simple activity “property marking” that 
reduces burglary rates. Rather it is mechanisms triggered by the intervention that 
interacts with particular contexts or contextual events. These mechanisms can be 
activated or deactivated in many, many ways, some of which would be beyond the 
control of intervention designers. What characterizes the effects of interventions is 
therefore that they depend on factors that are emergent and unpredictable and that 
they could lead to non-linear outcomes (e.g. outcomes may diminish over time). In 
order to predict outcomes, increasingly refined CMO configurations must therefore 
be developed, a process that in principle can continue indefinitely, but at some point 
a pattern of regularity in mechanisms over different contexts will emerge leading to 
a much higher confidence in the prediction of outcomes (197).  
But it is important to understand that since there can be many underlying 
mechanisms, whose refinement, relationship and dominance may be different from 
context to context, there will never be a deterministic relationship between 
intervention activities and desired outcomes, (202). Consequently, the regularity 
pattern are sometimes described as a “partial regularity” (202) meaning that there 
will always be exceptions to the rule in replicating the outcomes of previous 
experiences. So, when the Cochrane review on telehealthcare for COPD patients 
describe the search for why telehealthcare works in the following way: “Typically, 
in COPD, there are a number of ingredients including some education, some 
assisted planning, emotional support, pragmatic advice, monitoring with 
equipment, etc. which, taken together, may or may not benefit the patient” (26, p3),
realists would claim that there is no point in searching for those “active ingredients” 
in interventions. Instead, if intended outcomes were not achieved, it is always 
possible to learn lessons that can be used to develop theories that can help future 
designs of interventions and evaluations. It is therefore paramount to investigate 
underlying reasons for activating/deactivating mechanisms and making those 
explanations publically available. This task is challenging in critical realism; it is 
illustrated that what was initially a simple intervention with a single outcome, can 
quickly become so nuanced that it becomes challenging to report. Imagine then the 
difficulties in seeking to explain the results from a cost-effectiveness evaluation of 
telehealthcare that is a much more complex intervention with several interacting 
activities and three outcomes (mortality, health-related quality of life and costs).  
Critical realists have been criticized for not providing an operational methodology 
for the conduct of realistic evaluation (203,204) and evaluators have therefore 
struggled to implement realistic evaluation in practice (204). This implicates that it 
is generally difficult to empirically test applied realist theories, which risk bringing 
realistic evaluation into conflict with principles of scientific investigation, where 
theories should be falsifiable (205). Although some improvements have been made 
recently (199,206), realistic evaluation has been criticized for still being unclear in 
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its definition and operationalization of contexts, mechanisms and outcomes and 
especially in describing how they are distinguished (204). 
6.3. CURRENT MEDICAL RESEARCH COUNCIL GUIDANCE 
FOR EXPERIMENTAL EVALUATION OF COMPLEX 
INTERVENTIONS
While adhering to the positivistic paradigm, The Medical Research Council (MRC) 
have published guidance of conducting evaluations of complex interventions that 
insists that experimental evaluation should be at the core of evaluation in order to 
maintain internal validity of the cause-and-effect conclusions drawn (207). It would 
otherwise be difficult to separate observed outcomes from what would have 
happened anyway (208). But at the same time, it is acknowledged that it is 
challenging to replicate findings from individual studies and theories and qualitative 
research is therefore necessary in order to provide lessons for future implementation 
(207).  
In the MRC framework, the term “complex” is used to describe interventions that 
include several interacting components consisting of a large number of activities 
and a high frequency of interaction between these components (207). Furthermore, 
interventions are complex when several groups or organizational levels are involved 
and when potential relevant outcomes is large or the required behaviors of those 
targeted by the intervention is difficult (207). In this view, telehealthcare is 
complex, since it requires changed behaviors from both patients and healthcare 
professionals and involves not only a device with measurement peripherals, but also 
some training and a changed work flows and organization in and between 
healthcare delivery sectors. This complexity of telehealthcare solutions are 
acknowledged in the Cochrane review of telehealthcare to COPD patients (26) and 
by some health economists (209).  
In order to develop and evaluate complex interventions, a systematic framework is 
recommended by MRC that consist of four more or less sequential phases (207). 
First, a development phase, where theory and existing evidence relevant for the 
intervention is explored that should allow investigators to formulate a logical model 
and hypotheses of intervention outcomes and to identify mediating or moderating 
variables. This could be based on traditional systematic reviews of the literature and 
other theories. Qualitative methods could assist in order to describe the inputs that 
the intervention requires, how the components fit together and to identify 
underlying processes that produces outcomes (207). Second, a pilot and feasibility 
phase is necessary to test the acceptability and applicability of the intervention 
activities and evaluation approach that have been created so far. This may take the 
forms of small scale models of the actual intended intervention and evaluation 
design or as designs that investigates the main uncertainties with implementation or 
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evaluation identified in the development phase. Examples of tests include 
estimating recruitment, retention, compliance, delivery and the relevance of 
outcomes. Qualitative methods could assist in addressing potential barriers or 
enablers affecting those aspects. It should also point to intervention components 
that are essential and which can be added, adapted or eliminated. Depending on the 
results of these studies further refinement of intervention components or evaluation 
are needed (207). Third, full-scale evaluation should be adopted in order to assess 
effects. Randomized designs must always be considered with large samples. 
Multilevel designs or some other variant of the basic RCT design are preferred to 
account for technical or ethical challenges with randomization (207). Process 
evaluations nested in the trial are recommended in order to explain differences in 
expected and actual outcomes as well as to identify facilitators or barriers to 
implementation into routine practice (208). A nested health economic evaluation 
should also be included to make the trial “more relevant” for decision-making and 
to assist in getting the evidence translated into practice (207). Finally, an 
implementation phase concludes the evaluation effort and includes scientific 
publication of results and descriptions of experiences that contain more accessible 
information and specific recommendations for deployment (207). 
The main strength of the MRC framework is that it underlines that evaluation is a 
process, not an approach. This could in theory solve some of the challenges faced 
in trial-based economic evaluation of complex interventions by theoretically 
allowing refinement of intervention and identification of important factors that 
could potentially impact evaluation results before full-scale deployment of large 
and complicated initiatives and evaluations such as CRTs. It would allow some 
organizations, healthcare professionals and patients to become more experienced 
with the implementation of the intervention (accounting for some learning curve 
effects) and it could point investigators to potential confounding factors, wider 
organizational implications of implementation or how intervention activities are 
locally adapted.  
Many of the MRC recommendations can be found in the TeleCare North evaluation 
and to a lesser extent in the KIH initiatives. The development of the intervention 
was largely decoupled from the evaluation in both TeleCare North and KIH. A 
theory of change and work flow analyses was applied in the KIH initiatives (115), 
but was largely neglected in TeleCare North. Instead, TeleCare North built on 
experiences gained from especially a pilot trial with nested economic evaluation in 
North Denmark Region (109,172) that demonstrated a potential for cost-
effectiveness after 6 months measured as cost per QALY. In a sense, some would 
argue that this study functioned as both the underlying theory and the pilot study of 
the TeleCare North trial. This pilot study involved a non-commercial version of a 
tablet and peripherals and a hospital-to-home intervention and therefore required a 
refined technical solution and organization in order to make use of newer and more 
available technology and the cross-sectorial requirements. In seeking to update the 
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intervention, much attention was given to the feasibility of cross-sectorial 
implementation and too little attention to working with mechanisms and contexts 
thought to lead to effectiveness and cost savings. The pilot study, although probably 
cost-effective due to cost-savings, demonstrated statistically insignificant 
effectiveness (incremental QALY=0.027) and did not include cost to municipalities. 
A more conscious approach to improving and testing particularly the effectiveness 
outcomes of the trial and the impact on municipality cost could therefore have been 
warranted prior to large-scale evaluation. In addition, the pilot study was 
implemented in a different organizational setting than TeleCare North eventually 
did. Working with how this changed context could influence the outcomes of the 
trial might have helped in explaining the ultimate outcomes of the trial. But none of 
the initiatives put underlying theories to the test before large-scale implementation 
and evaluation. TeleCare North did move forward to a large-scale multilevel 
clinical trial with nested economic evaluation that was accompanied by a qualitative 
process evaluation of facilitators and barriers to implementation. This was in reality 
not done in KIH (even though it was called a large-scale initiative, it actually 
contained five pilot studies). The KIH initiatives contained some process evaluation 
as well but not a trial-based economic evaluation. TeleCare North was also the only 
initiative to be published scientifically. It is always easier to be smart in hindsight, 
but in the spirit of including what we know now in order to inform future 
evaluations, it could be argued that although many of the recommendations from 
the MRC framework was incorporated into the design and evaluation process of 
TeleCare North, we might still have moved too quickly to large-scale 
implementation and testing.  
The MRC framework have been criticized for being too embedded in a clinical 
logic, for not engaging with complexity science and for having a tendency to 
oversimplify complex social reality (202,210,211). MRC presents a linear logic 
from a pre-specified program theory to large-scale implementation, which largely 
ignores the role of particularly context and that CMO-configurations needs to be 
refined before evaluation (210,211). Too little attention is therefore paid to its 
content in especially the development and feasibility phase (211). The largest role 
theory of context and mechanisms have in the MRC framework is in process 
evaluation that is suggested in the implementation phase in order to investigate 
reasons for discrepancies between trial outcomes and expectations (208). But 
process evaluations are not concerned with causality, but instead how interventions 
were implemented in practice and how outcomes were perceived by patients, 
healthcare professionals and other stakeholders (208). There is generally no 
feedback that can be used to quantify the effects that this implementation or these 
perceptions might have had on the outcomes of the evaluation. And then it becomes 
a little too late. So, the MRC framework is criticized for including the right topics 
or words, but without providing any real content of how to adapt an experimental 
evaluation setting to include context and mechanisms (202,210,211).  
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6.4. A REALIST SKETCH FOR HEALTH ECONOMIC 
EVALUATION OF COMPLEX TELEHEALTHCARE 
INTERVENTIONS
Some would rightfully state that it is impossible to have a standpoint in two 
different philosophies of science, meaning that experimental evaluation in general 
and trial-based economic evaluation by implication, cannot be truly realistic (198). 
However, albeit a difficult and daunting task, it does not exclude that lessons may 
be taken from one standpoint to inspire the development of the other. But how can a 
more theory-based evaluation approach be incorporated into trial-based economic 
evaluation that would maintain high internal validity while at the same time allow 
for greater external validity in order to keep answering what course of action is 
cost-effective and for whom, but also seek to focus more on why and under what 
circumstances telehealthcare is cost-effective?  
There have been some developments into ways of incorporating more concrete 
realist thinking into experimental evaluation, e.g. realist randomized trials (200) and 
recently realist complex intervention science (211). But these more theory-based 
approaches to evaluation tend to be focused on explaining effectiveness (196). 
However, it should not be a controversial idea to seek starting a research agenda for 
realist health economic evaluation; the fact that health economists insist that 
pragmatic trials are better vehicles than explanatory trials for economic evaluations 
and that a lot of effort are put into sensitivity analyses (i.e. a right shift on an 
internal to external validity continuum) is a manifestation of an underlying logic 
that very few context-independent and deterministic relationships between 
interventions and outcomes can be found and that changed prerequisites and 
assumptions (i.e. changed theory) impact outcomes. This leads to the first principle. 
Principle one: Trial-based economic evaluation of complex 
telehealthcare interventions should focus on external validity by 
developing and testing theory of what causes change mechanisms to 
be activated/deactivated in order to produce certain outcomes and 
incorporate how these are dependent of context.  
An adapted MRC framework for evaluation could be a starting point. Fletcher and 
colleagues have in July 2016 published an article suggesting several general 
techniques to include more “realism” into experimental evaluation studies by 
recommending that all MRC phases should be utilized and adapted (211).  
In the development phase, some form of mixed-methods reviews can be used to 
synthesize the overall effects of interventions while also addressing how 
interventions work and interacts with context (211). Purposively sampled case 
studies (interviews, observations or surveys) are suggested as a way to explore 
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hypothesized theoretical mechanisms in different settings in order to understand 
how context interacts with mechanisms (211). Both activities should result in an 
initial program theory of change and explicitly describe how context would impact 
on the activation/deactivation of mechanisms (211).  
Below is a suggestion of a program theory meant to demonstrate the potential value 
of realism for trial-based economic evaluation. Comparative effectiveness in 
telehealthcare might be achieved by “adherence”, i.e. that increased effectiveness is 
mostly feasible if telehealthcare makes it easier for patients to adhere to the 
treatment and care opportunities relevant for their disease (e.g. monitoring, training, 
smoking cessation, dieting and pharmaceutical therapy). Another program theory 
could be “patient capabilities”, i.e. that increased effectiveness is more achievable 
if telehealthcare allow new patient skills to be successfully developed in mastering 
COPD. Potential underlying mechanisms of change could be that these theories are 
only relevant if patients feel comfortable with the technology and are empowered 
by the opportunities to gain more access to counseling or support in managing their 
disease or in adhering to monitoring, training and medicine therapy. But it is also 
important to relate these program theories of effectiveness to program theories for 
costs. Under usual care, it could reasonably be hypothesized that increased severity 
of COPD leads to increased resource consumption and that there is some form of 
positive correlation between severity and resource consumption. However, a 
positive correlation does not exclude that all individual patients follow this trend.  
One program theory for lower costs could be called “optimization”, which means 
that some patients – presumably COPD patients with intermediate severity and risk 
of events - who are treated by specialized healthcare professionals under usual care, 
might be safely switched to less specialized care if they adhere to monitoring, 
pharmacological therapy and training by help from telehealthcare. Potential 
underlying mechanisms can be found in the reactions of healthcare providers and 
personnel involved in telehealthcare and it could be that in order to achieve lower 
cost by optimization, engagement in learning new ways to monitor and caring for 
patients by healthcare professionals is necessary. Another program theory for cost 
could be called “transference”, meaning that if increased patient capabilities could 
be achieved, then it would be possible to reduce the need for healthcare sector 
resources, because the patient’s themselves or their relatives become actively 
involved in learning to monitor and care for the disease. This would require a 
mechanism of trust and acceptance for transference of responsibility by patients 
and relatives and possibly convincing safety evidence as judged by health 
professionals. Lastly, contextual factors hypothesized as important for achieving 
increased effectiveness and lower costs should be presented. These could be found 
in areas such as the technology applied, the targeted patients and in the 
organizational structures in which telehealthcare is implemented. In TeleCare 
North, we have documented that the severity of COPD might play a role and an 
under-met need for care in municipalities might affect costs, but generally little 
explicit knowledge exist. So, an overall program theory for cost-effectiveness of 
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telehealthcare might be that two intermediate outcomes must be increased first in 
order to increase health-related quality of life or reduce mortality by telehealthcare, 
adherence and capabilities. These are also necessary in order for cost-savings to 
occur. But both effectiveness and cost outcomes are depending on several 
underlying mechanisms to be (de)activated and the context in which telehealthcare 
is implemented. 
A feasibility/pilot phase should be used to explore facilitators or barriers to 
implementation and the acceptability of participants and stakeholders in order to 
inform a revision of the intervention design and evaluation methods prior to large 
scale evaluation (211). However, there has been a tendency in feasibility studies to 
only explore if an intervention and evaluation is possible and acceptable or not; not 
what is possible and acceptable for whom and under what circumstances (211). 
More importantly in this phase; developed program theories should be put more to 
the test before large-scale evaluation in order to investigate if and how interventions 
or evaluation should be adapted before large-scale evaluation and to point to 
potential areas for learning effects and organizational implications (it is too late 
when evaluation has begun). It is therefore important to design interventions and 
develop evaluation simultaneously to allow for testing different concrete 
intervention activities or components (e.g. device and peripherals, training, 
monitoring, support) that could achieve intermediate outcomes and lead to the 
activation of mechanisms. This should be done across a range of purposively 
selected contexts that would allow for refining the underlying program theory 
(CMO configurations) (211). If it is appropriate, a multi-arm pilot study can be used 
to assist in identifying components that are essential in activating/deactivating 
mechanism but also to assess if some components could be adapted or eliminated 
(211).  
Fletcher and colleagues have argued (211) that the evaluation phase should utilize 
developments in realist randomized trials (200), which are large-scale mixed-
methods trials, that assess within-trial effects of interventions and how they are 
mediated by mechanisms and moderated by context as well as developing theories 
about factors that would enable or prohibit effectiveness in other contexts. Realist 
trials would usually apply complex designs, such as CRTs or other variants of 
RCTs and place emphasis on multi-arm or factorial designs in estimating the 
effectiveness of separate intervention components and in combination (200). 
Analytically, realist trials would also apply statistical mediation analysis in order to 
assess the activation/deactivation of mechanisms (200). In doing so, realist trialists 
would underline that it is not the concrete activities in interventions that are 
important but how they activate/deactivate mechanisms (200). Interaction with 
context is explored by heterogeneity analyses and by pre-planned coordination with 
other trials applying the same program theory between implementation contexts 
(200). Qualitative methods would be included as process evaluations meant to 
identify what the intervention did and point to a need for refining mechanisms or 
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refining how context affected them, but also point to relevant additional variables to 
be used in the follow-up measurement (200). 
To my knowledge, there has only been one initiative that has used a well-founded 
theoretical approach in telehealthcare research. Perhaps based on the discussion in 
the aftermath of the results of telehealthcare in the WSD in the UK, initial work 
began in 2013-2014 on applying theory-based principles to telehealthcare on a new 
initiative testing the effectiveness and cost-effectiveness of telehealthcare in the UK 
(the “TECH model” applied in the later implemented Healthlines studies) (212). In 
developing the conceptual model, a systematic review to assess evidence of effects 
combined with a realist synthesis of qualitative investigations of patient experiences 
with telehealthcare a crude program theory was formulated (212). The model was 
then adapted to their empirical context by a qualitative study tapping into the 
potential role of telehealthcare valued by both patients and different health 
professionals and a survey to patients investigating the presence of and interaction 
of contextual factors on the emergent mechanisms (212). Based on these sources, a 
draft model was formulated to capture how, why and under what circumstances 
telehealthcare might bring about desired outcomes and this draft model was refined 
by a workshop consisting of representatives from both patients, healthcare 
personnel and providers, commissioners of services and academics which lead to 
the development of an initial program theory (212).  
The results from this process identified three theoretical “components” for 
effectiveness and cost-effectiveness in telehealthcare (212). One was “self-
management” which were hypothesized to be activated by several activities in 
interventions, e.g. by training behavior change techniques, allowing for self-
monitoring of vital values, promoting self-efficacy, shared decision-making, 
motivational interviewing and personalized support from health professionals etc. 
(212). The second component was “treatment optimization” that could be activated 
in several ways, e.g. by risk stratification of patients, treatment intensification, 
using evidence-based protocols and regular review, promoting medicine adherence 
etc. (212). The third component was “care coordination” activated by shared 
records, effective communication between healthcare providers, regular monitoring 
of system performance etc. In addition, several important contextual factors were 
hypothesized to influence the effects of these components (e.g. the level of 
engagement of patients and primary care professionals, type and severity of disease 
and the wider health system in which interventions are embedded) (212).  
The TECH program theory was then used to design two strategically coordinated 
telehealthcare pragmatic trials with nested 12 months trial-based economic 
evaluations and process evaluations (213). The chosen participants were patients 
with depression (609 patients, 307 received telehealthcare) and patients with 
cardiovascular risk (641 patients, 325 received telehealthcare) (213). The setup 
consisted of the same participating general practices, intervention- and research 
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staff and the same underlying theory of components, mechanisms and contexts. But 
the specific activities in each intervention, the data analyses and reporting were 
different from study to study (213). In July 2016, the results from the trial-based 
economic evaluations of both trials were published and provided mixed results 
(214,215). The cardiovascular trial concluded that it was likely that the Healthlines 
telehealthcare intervention for cardiovascular risk was cost-effective (net monetary 
benefit of £116 (95% CI 58 to 291) and a 77% probability of cost-effectiveness at 
threshold of £20,000 per QALY) (214). However, the depression trial concluded 
that the Healthlines telehealthcare intervention was unlikely to be cost-effective (net 
monetary benefit of -£143 (95% CI £164 to -£122) and a 30% probability of cost-
effectiveness at threshold of £20,000 per QALY). This mixed evidence leads to the 
second principle. 
Principle two: Trial-based economic evaluation of complex 
telehealthcare interventions should be part of a continuous strategic 
process of knowledge creation that should ultimately answer 
questions of what was cost-effective for whom, why and under what 
circumstances. Since only partial regularities can be found, it is not 
an approach designed to be a one-off verdict of what was cost-
effective or not. 
Traditional health economists would be disappointed by the results from 
Healthlines and might even claim that there is no need to adopt realistic evaluation 
methods in health economic evaluation, since evidence is still mixed. But is that 
fruitful? We have done this for 20 years without much progress (28). Not 
surprisingly, a critical realist would argue that this mixed evidence is exactly why 
we need realistic evaluation and that disbanding a theory-based approach is 
premature. Researchers and practitioners always learn something - both from 
successes and failures - that can be used in order to inform the theoretical logic 
underlying future studies. The journey to theory validation and refinement has only 
just begun. And it is also worth remembering that critical realists would argue that 
the world is so complex that unforeseen events always arise that affects outcomes in 
some way. But what realistic evaluation does, is that it focuses attention to working 
with contexts, mechanisms and outcomes and to making these experiences explicit 
and available for other researchers. 
The published process evaluation points to some indications of the need for 
refinement in implementation in the Healthlines trials (216). In general, the overall 
theory is concluded as sound for developing interventions and for assessing effects 
and implementation occurred largely as planned. However, there were several 
contextual factors that could have affected effectiveness in both trials. In the 
depression trial, there were problems with engaging patients because they had busy 
lives and preferred a therapeutic approach to behavioral therapy and in the CVD 
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trial, patients were not really interested in making lifestyle changes, but joined the 
trial for altruistic reasons. Finally, primary care was not engaged either (216). 
There are several considerations for future theory-based interventions and 
evaluation to be made based on the experiences with the TECH model and 
Healthlines studies that relates to context, mechanisms and outcomes. First, more 
work should be done in distinguishing between what is underlying mechanisms of 
change, context and what are outcomes, e.g. in the Healthlines studies it is not 
completely clear if self-management is a response to resources offered (a 
mechanism) or an intermediate outcome leading to more ultimate outcomes. It is 
also not clear if patient engagement is a mechanism or a context (it is described as 
context, but could also be a response to the intervention?). Second, more work on 
linking mechanisms and context to costs should be conducted and to describe how 
they are linked with effectiveness mechanisms.  Third, it could also be time to ask 
ourselves again if the effectiveness part of cost-utility analyses (i.e. QALYs) is the 
most relevant outcome in its existing form in a hierarchy of outcomes for 
telehealthcare evaluation. Looking across recent trial-based economic evaluations 
of telehealthcare, a regularity has arisen, i.e. the incremental QALYs are still small 
and statistically insignificant (incremental QALYs in WSD (0.012, not significant) 
(125), Telescot (0.017, not significant) (127), TeleCare North (0.013, not 
significant) (129) and the two Healthlines studies (0.012, not significant (214); and 
0.031, not significant) (215). This keeps being consistent with findings from 
Bergmo that published similar results from a review of QALY gains in 
telehealthcare research prior to the WSD publications (217). I do not recommend 
stopping the effectiveness part of economic evaluation, because we need to assess 
whether the intervention is at least as good or safe as comparative interventions. But 
as long as they are, and this seems to be case, the largest effects on outcomes might 
be found in minimizing costs, effectively reducing the economic evaluation to a 
cost-minimization analysis. It could also implicate that we need to be prepared to 
find additional effectiveness outcomes in trial-based economic evaluation, such as 
better access to treatment and care or more consistent care, even if this would 
reduce economic evaluations to cost-effectiveness analyses (although utility could 
also be access to treatment and care, but will require quantification in order to be 
applied for comparison with other technologies with the same objective). Bergmo 
have also previously suggested that benefits of telehealthcare instead of QALYs 
might be found in other outcomes such as access or waiting time (217). Fourth, 
although much effort was put into the development of the theoretical model for the 
Healthlines trials, it seems that much more attention could be made in testing theory 
and interventions before large-scale evaluation. That two GPs were used in “a run-
in period” is mentioned in the trial protocol (213), but it seems that this was to test 
feasibility of implementation rather than testing and refining theory of mechanisms, 
context and outcomes. More systematic work on testing could be warranted before 
further evaluation in order to explicate or refine cost and effectiveness mechanisms 
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leading to outcomes and how context would affect their relationship as described 
above. This leads to the third principle. 
Principle three: Trial-based economic evaluation of complex 
telehealthcare interventions should have an organization for testing 
CMO-configurations which would allow for climbing up the learning 
curve before large-scale evaluation. 
In general, mixed methods are recommended as part of getting more realism into 
experimental evaluation and cross-disciplinary research networks with researchers 
from multiple disciplines and practitioners is a requirement for good intervention 
science (200). But this needs an organization. I would propose that it could 
probably be found in the quality improvement (QI) tradition that is deeply 
embedded in practice. On the conceptual level, the QI tradition is especially useful 
for trial-based economic evaluation, because it is inherently realistic in its 
evaluation approach and terminology and because there is a particular focus on 
documenting learning. QI seeks to build knowledge of how to make improvements 
(218). This could be achieved by changing the characteristics of a product or 
service, its delivery process or the entire system to bring about predicted 
improvements. Central to QI is two things: First, predictions of improvements are 
based on an explicit theory and hypotheses of change. Second, sequential planned 
experimentations are used to test theories in practice. If changes did not lead to 
predicted improvements in the experiments, it is necessary to identify and describe 
the context that affected change in order to refine the theory (QI would identify 
those based on anomalies or variation in outcomes, so mixed-evidence is 
expected!). A framework to support this knowledge creation is the “Model for 
improvement”, which applies both deductive and inductive learning phases in so-
called Plan-Do-Study-Act (PDSA) cycles. In the “Plan” phase, a theory of why a 
concrete intervention would lead to improvement is developed and an experiment to 
test the intervention and theory is designed. In the “Do” phase, the test is conducted 
and any unexpected observations or problems are documented. The “Study” phase 
is concerned with analyzing data where a comparison with predictions are made and 
described. In the “Act” phase, refinements are made to the intervention and/or 
theory. By repeated use of experimentation by PDSA cycles, knowledge of what 
works, why and under what circumstances is increased and more confident 
predictions can be made. QI uses small scale and local experiments in order to 
develop and study interventions that should bring about improvements and in a 
MRC optic, the QI tradition is therefore most relevant in the intervention 
development and feasibility/pilot phase (218). The QI tradition could therefore be 
precisely what trial-based economic evaluation needs in order to bridge the gap 
between theory development and large-scale implementation and evaluation.   
Many Danish regions has a huge focus on the model for improvement and have 
organizational structures that support the initiation, testing and dissemination of 
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quality improvement efforts across hospitals, e.g. DEFACTUM in Central Denmark 
Region (www.defactum.dk), the improvement organization in North Denmark 
Region(http://www.rn.dk/Om-Region-Nordjylland/Organisationsbeskrivelse/Forbedring)and Centre 
for Quality in the Region of Southern Denmark (www.centerforkvalitet.dk). But in 
Denmark, it is almost an embedded culture that the QI movement and comparative 
outcomes research are separate disciplines, where comparative outcomes 
researchers may have a tendency to be skeptical of the concept of “quality” in QI 
that is generally defined as fulfilling customer needs and see their interventions as 
quick fixes rather than sound interventions based on rigorous evaluation methods. 
QI practitioners on the other hand could advocate that comparative outcome 
researchers are not aware of real practice and oversimplify reality in laboratories. In 
order to utilize this organization, leadership is a prerequisite from both universities 
and regions in order to bring academics and practitioners together to try something 
different. On one hand, QI practitioners should be willing to accept that there is a 
hierarchy of evidence and that experimental trials are at the heart of this hierarchy. 
Equally important, it also needs a larger community of health economists that have 
had the frustrating experience of being challenged to explain the outcomes of trial-
based economic evaluation. This leads to principle four. 
Principle four: Trial-based economic evaluation of complex 
telehealthcare interventions should challenge existing general good 
practices of how to conduct and report trial-based economic 
evaluation. 
In order to be more able to develop, validate and refine CMO configurations, some 
changes to how trial-based economic evaluation should or should not be conducted 
and reported is necessary. One is tackling the fear of “data-dredging” that could 
lead to false positive results. Clinical trials are usually powered to detect changes in 
a single primary (usually efficacy or effectiveness) outcome which mean that it is 
hard to find statistically significant results in secondary analyses such as in 
secondary outcomes, in mediation analyses or in subgroups. This challenge should 
be taken seriously especially if studies are meant to inform clinical practice. 
However, it is already acknowledged that the purpose of trial-based economic 
evaluation is different because they are meant to inform funding decisions. Those 
decisions do not have to be dependent on statistical significant certainty and the 
only requirement is that any secondary analyses are pre-specified in a study 
protocol. But in complex telehealthcare interventions, it would only be feasible to 
pre-specify mechanisms and contexts that are included in the program theory. 
Central to realism is that unanticipated events would always occur that affects 
outcomes and those events are difficult to foresee a priori. Reporting how these 
unforeseen events affected mechanisms and cost-effectiveness is central to the 
refinement of theories that can be used in future design of interventions and 
evaluation, not only locally but also for researchers conducting mixed-methods 
systematic reviews. So, instead of automatically rejecting post hoc secondary 
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analyses, good practices for trial-based economic evaluation of complex 
telehealthcare interventions should actually recommend them and include them in 
reporting guidelines for trial-based economic evaluation (e.g. as extensions to the 
CHEERS-checklist). 
Another challenge is the fear of comparing complex telehealthcare interventions 
that involves different concrete intervention activities and for changing concrete 
interventions to suit the local context in which it must operate when evaluation has 
begun. The strength of focusing on mechanisms is that it is not the concrete 
activities that directly affect outcomes, but underlying causal mechanisms. So, as 
long as the underlying logic or program theory is the same, comparing interventions 
with the same program theories should be possible and there should be more room 
for local adaptations in concrete intervention activities.  
The above was meant as a sketch of some normative overall principles for trial-
based economic evaluation of complex telehealthcare interventions that should be 
discussed and developed further. It is meant as a suggestion for how to move 
forward and is not a finished concrete concept to be tested in practice and how can 
it be when sketched by a single author new to the field without existing research or 
examples to build on. 
Although, I have suggested possible ways to adhere to the suggested principles that 
can be built on very recently published evaluation research and described how 
existing organization in particularly the Danish regions can be strategically utilized, 
it is still a huge investment in time and effort to change existing trial-based 
economic evaluation of complex telehealthcare interventions. I would therefore like 
to finish off by giving voice to Bonell and colleagues who were one of the first 
research groups that suggested an integration of experimental and realistic 
evaluation in 2012 that addresses this issue in the following way:  
”It might be argued that our plans are impossible because of the 
expense and time required for such painstaking assessment […]. we 
argue that this systematic approach would ultimately be more time- 
and cost-efficient than current, uncoordinated efforts. There are 
already huge numbers of evaluation studies conducted that focus on 
an unsystematic array of combinations of intervention components 
and settings, and which, for the reasons outlined above, often provide 
a poor basis for decision-making by policy-makers and 
practitioners”(200, p2305) 
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This thesis contains the results from the Danish TeleCare North trial meant 
to assess the effectiveness and cost-effectiveness of a telehealthcare solu-
tion implemented in North Denmark Region from 2013-2015. The TeleCare 
North trial demonstrated no difference in health-related quality of life and the 
telehealthcare solution was not cost-effective for all included COPD patients. 
But there was a potential to target the solution to patients with severe COPD. 
The results also indicate that implementation could have a strong impact on 
cost-effectiveness, more so than health- or socio-demographic factors.
The results from the TeleCare North trial were used directly in a national 
decision to implement the telehealthcare solution to patients with severe 
COPD in Denmark and lead to considerable debate nationally. This debate 
could be viewed as an actual account of the usefulness of health econom-
ic evaluation for decision making meant to inform adaptation of the health 
economic evaluation approach.
Based on developments in realist evaluation and experiences with conduct-
ing the evaluation of TeleCare North, four principles for health economic 
evaluation of complex telehealthcare interventions is outlined in order to 
facilitate future health economic designs of telehealthcare that should ulti-
mately answer if telehealthcare is cost-effective, for whom, why and under 
what circumstances.
